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Abstract
There is growing interest in the role of vascular disease in accelerating age-related
decline in cerebrovascular structural and functional integrity. Since an increased
number of older adults are surviving chronic diseases, of which cardiovascular
disease (CVD) is prevalent, there is an urgent need to understand relationships
between cardiovascular dysfunction and brain health. It is unclear if CVD puts the
brains of older adults, already experiencing natural brain aging, at greater risk for
degeneration. In this thesis, the role of CVD in accelerating brain aging is explored.
Because physical activity is known to provide neuroprotective benefits to brains of
older adults, the role of physical activity in mediating disease effects were also
explored.
Using novel neuroimaging techniques, measures of gray matter volume and
cerebrovascular hemodynamics were compared between groups of coronary artery
disease patients and age-matched controls, to describe regional effects of CVD on the
brain. In a sub-set of patients, imaging measures were repeated after completion of a
6-month exercise training, part of a cardiac rehabilitation program, to examine
exercise effects. Differences in cerebrovascular hemodynamics were measured as
changes in resting cerebral blood flow (CBF) and changes in cerebrovascular
reactivity (CVR) to hypercapnia (6% CO2) using a non-invasive perfusion magnetic
resonance imaging technique, arterial spin labelling (ASL). We found decreased brain
volume, CBF and CVR in several regions of the brains of coronary artery disease
patients compared to age-matched healthy controls. The reductions in CBF and CVR
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were independent of underlying brain atrophy, suggesting that changes in
cerebrovascular function could precede changes in brain structure. In addition,
increase in brain volume and CBF were observed in some regions of the brain after
exercise training, indicating that cardiac rehabilitation programs may have
neurorehabiliation effects as well.
Since, CBF measured with ASL is not the [gold] standard measure of functional
brain activity, we examined the regional correlation of ASL-CBF to glucose
consumption rates (CMRglc) measured with positron emission tomography (PET), a
widely acceptable marker of brain functional activity. Simultaneous measurements of
ASL-CBF and PET-CMRglc were performed in a separate study in a group of older
adults with no neurological impairment. Across brain regions, ASL-CBF correlated
well with PET-CMRglc, but variations in regional coupling were found and
demonstrate the role of certain brain regions in maintaining higher level of functional
organization compared to other regions.
In general, the results of the thesis demonstrate the impact of CVD on brain
health, and the neurorehabiliation capacity of cardiac rehabilitation. The work
presented also highlights the ability of novel non-invasive neuroimaging techniques
in detecting and monitoring subtle but robust changes in the aging human brain.
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CHAPTER 1

"A good head and a good heart are always a formidable combination" Nelson Mandela

1.1

Clinical Relevance

Cardiovascular disease is one of the most prevalent chronic diseases among older
adults1, accounting for the second highest healthcare cost in Canada2. One in five
Canadians over the age of 65 has a history of coronary artery disease (CAD), which is the
most prevalent form of cardiovascular disease3. As the population of older adults
continues to climb exponentially4 and the survival rate for CAD continue to increase, an
overwhelming need to understand disease effects and improve quality of life in the
elderly are imperative. At the societal level, age-related chronic diseases such as CAD
pose an obvious financial and social burden, while at the individual level, the gradual loss
of function from chronic diseases pose a threat to successful aging.
Rowe and Kahn defined successful aging as a combination of the ability to
maintain a low risk for disease and disease-related disability, preserve a high mental and
physical functional capacity and continue an active engagement in life5. Considerable
efforts are being made to achieve successful aging in older adults with CAD, including
primary and secondary interventions aimed at minimizing risks of recurrence and
improving overall cardiovascular function3. However, recent evidence6 points to the
possibility of comorbid neurological impairments that could threaten the mental capacity
of CAD patients and curtail their active engagement in life.
It is well known that brain atrophy, cerebral hypoperfusion, white matter disease
and impairments in cognitive function are associated with risk factors for CAD in
asymptomatic older adults6. Longitudinal and epidemiological studies in individuals with
1

increased risk factors for CAD have concluded that risk factors such as hypertension,
diabetes and high blood cholesterol advance age-related changes in the structure and
function of the brain7–12. Some researchers have gone as far as suggesting that dementia,
including Alzheimer's disease, could be associated with vascular disease, since chronic
vascular dysfunction can limit adequate blood supply to the brain and in doing so trigger
a cascade of events that eventually lead to neurodegeneration13,14. However, the direct
impact of CAD on the structure and function of the aging brain has not yet been
characterized. Identifying the impact of CAD on the brain could aid in devising strategies
that facilitate successful aging in these individuals such as cognitive remediation and
physical activity.
The interaction of CAD, age and cerebrovascular degeneration is complex. Noninvasive neuroimaging techniques are crucial not only in studying this complex
interaction, but they are becoming clinically relevant for identifying, monitoring and
assessing clinical outcomes of CAD effects on the brain. This introductory chapter will
define CAD, discuss concepts of normal brain aging, review premature brain aging
associated with CAD risk factors, and discuss the role of physical activity in mediating
successful aging. A section is also dedicated to the discussion of the brain imaging
techniques used in this thesis to characterize CAD effects on the brain.

1.2
1.2.1

Coronary Artery Disease
Cardiovascular disease defined

The World Health Organisation defines cardiovascular disease as a class of
diseases that affect the heart and blood vessels within the heart, within the brain and
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around the body (www.who.int, Fact sheet 317). In 2009 an estimated 1.6 million
Canadians had heart disease or stroke and 1 in 3 adults over the age of 65 were diagnosed
with heart disease2. The cost of care for cardiovascular diseases in Canada was over
$22.2 billion in 20002 and is projected to rise as the number of older adults continue to
increase15. Similar enormous economic burden for cardiovascular disease has been
reported for other industrialized countries such as the United States15,16, Europe15,16,
Australia15 and Japan16. Cardiovascular disease can be grouped into two types;
I.

Diseases due to atherosclerosis, namely, coronary artery diseases including
myocardial infarction, cerebrovascular diseases such as stroke, and vessel
diseases such as hypertension and peripheral vascular disease.

II.

Diseases due to damage to the heart or disorder of the heart, namely: cardiac
arrhythmias, congestive heart failure, cardiomyopathy meaning abnormal heart
muscle, congenital heart disease, which refers to malformation of the heart from
birth defect, and rheumatic heart disease, which is due to damage to the heart
muscle/valve from streptococcal bacteria4.
Atherosclerotic diseases are the most common form of cardiovascular disease,

affecting mostly adults over the age of 65 and contributing to almost 80% of the entire
cardiovascular disease burden4. Coronary artery disease, being the most prevalent form is
an inflammatory response to atherosclerotic lesions in coronary arteries17. The rest of this
section will focus on CAD and discuss the pathogenesis, risk factors, clinical presentation
and current therapeutic interventions for CAD. First, a brief review of coronary
circulation is presented, because abnormal circulation is a significant part of CAD
pathophysiology.
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1.2.2

Review of coronary circulation

This review is culled from Principles of Anatomy and Physiology textbook by Tortora and
Derrickson18 and review articles by Ramanathan and Skinner19, Feliciano and Henning20 and by
Muller-Delp21.

All circulation to the heart comes from the aortic root, which branches out to the
right coronary artery (RCA) and left coronary artery (LCA). The RCA and LCA run on
the surface of the myocardium and are referred to as the epicardial or conduit vessels, as
they offer very little resistance (5%)20 to coronary flow. The RCA and LCA branch out to
more epicardial vessels that divide further into smaller branches as the vessels travel
deeper to supply the transmural myocardium. These subendocardial vessels are the
resistance vessels that dilate during increased myocardial oxygen demand to increase
coronary blood flow. The RCA and branches from the RCA supply blood to the right
atrium, right ventricle, posterior wall of left ventricle, and posterior portion of the
interventricular septum. On the other hand, the LCA and branches from the LCA supply
blood to the left atrium, lateral and anterior wall of left ventricle, and reminder of the
interventricular septum. The junction at the aortic root where the coronary arteries arise
are controlled by the aortic value which open during systole to allow blood flow to the
systemic and central arteries, and close during diastole to allow blood flow to the
coronary arteries. Therefore unlike all arteries in the body, which are perfused during
systole, the coronary arteries are mostly perfused during diastole. This is because, during
systole the contraction of heart muscles compresses the cardiac tissue including the
subendocardial coronary arteries, and only when the heart muscle is relaxed at diastole is
the myocardium perfused by the coronary arteries. The increased left intraventricular
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pressure during systole forces the aortic valve to open to the aorta while closing to the
coronary arteries, and when the pressure in the left ventricle rapidly drops during
diastole, the aortic valve closes to the aorta and opens to the coronary arteries. The back
pressure from this pushes blood into the coronary arteries, perfusing the myocardium.
At rest, coronary blood flow is approximately 250 ml/min19 or 0.8ml/min/g of
heart muscle19, which can increase up to fivefold during exercise. The heart extracts up to
80% of the oxygen in arterial blood, nearly three times the amount consumed by the rest
of the body19. Hence, the energy demand of the myocardium is met primarily by
increased blood supply via vasodilation of resistance coronary vessels. The magnitude of
the increase in coronary blood flow to accommodate increased demand is often referred
to as coronary reserve. Coronary reserve is governed primarily by coronary vascular tone,
which in turn is regulated by local metabolic demand, neuronal influences (sympathetic
and parasympathetic stimulation) and flow-dependent endothelial control (figure 1.1).
For instance, hypoxia directly triggers vasodilation of coronary arteries and also the
accumulation of adenosine, a potent vasodilator. At rest, autoregulatory mechanisms
maintain a constant coronary blood flow over a range of mean arterial pressures from 45
to 150 mmHg20 and is essentially mediated by the same factors mentioned above that
mediate coronary reserve. If pressure changes beyond this range, coronary blood flow
becomes directly dependent on perfusion pressure. In general, coronary vascular tone is
determined by the coordination of all three control mechanisms (figure 1.1 and 1.2) and
the influence of each mechanism varies along the vascular tree. Aging can modify the
regulation of coronary circulation inducing gradual reduction in blood flow at rest and
with increased demand. Endothelial dysfunction, arterial stiffness and left ventricular
5

hypertrophy are some of the age-related changes that can affect coronary circulation22,23.
CAD, on the other hand, exacerbates age-related dysfunction in regulation of coronary
circulation.

Figure 1.1: Vascular disease modulation of vasodilation mechanisms of coronary
arteries.

EDRF = Endothelium-derived relaxing factor. Solid lines indicate direct influence, broken lines
indicate secondary influence and red diagonal crosses indicates impairment of normal regulation.
Adapted from Ramanathan and Skinner19
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1.2.3

CAD impairment to coronary perfusion
The impact of CAD on coronary circulation is significant to the function of the

heart and equally important to the supply of blood to the brain. The brain, much like the
heart, does not maintain a reservoir of energy substrates to help meet its energy demand.
Hence, an increase in local metabolic demand will result in rapid hyperaemia to the
corresponding tissue. As such, the brain and the heart are highly sensitive to insufficient
supply of blood flow, that is, ischemia. In the heart, ischemia can be a consequence of
narrowed vessels, referred to as coronary stenosis, or impairment in vasodilatory
mechanisms due to atherosclerosis, diabetes or hypertension24. Vascular disease
processes affect not only the vasodilation mechanisms, but they can impair the normal
regulation of coronary circulation at rest and modulate vasoconstriction factors, as shown
in figures 1.1 and 1.2. Atherosclerosis facilitates endothelial dysfunction by inhibiting the
release of nitric oxide (NO)20,21, blunting vasodilation, and by increasing the production
of vasoconstrictor factors such as endothelin20,21. Furthermore atherosclerosis can cause
transient narrowing of coronary arteries, known as coronary spasm, by abolishing NOmediated vasodilation and by increasing vasomotor tone at rest20.
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Figure 1.2: Vascular disease modulation of vasoconstriction mechanisms of
coronary arteries

ET-1 = Endothelin-1. Solid lines indicate direct influence, broken lines indicate secondary influence
and red diagonal crosses indicates impairment of normal regulation.

Adapted from Ramanathan and Skinner19

1.2.4

Pathogenesis of coronary artery disease
Atherosclerosis is the primary cause of CAD. It often occurs within the epicardial

coronary arteries and is viewed as an inflammatory process in response to vascular
injury25. Since the mid-19th century, the accumulation of lipids in arterial wall was
known to produce atherosclerotic lesions25, but the notion of vascular injury was only
proposed in the mid 1980's25. Atherosclerosis is a progressive syndrome that starts off
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with infiltration of lipoproteins in the intima of coronary arteries called fatty streaks,
advancing to build up of lipids that adhere to smooth muscle lining forming plaques17,25–
27

. The plaques disrupt the endothelium, finally triggering an inflammatory response to

the fibrous caps of the plaques which then rupture and occlude vessels17,25–27. This
process is complex and beyond the scope of this thesis. Below, a schematic of the
simplified atherosclerotic process is shown in figure 1.3.
The common clinical outcomes of atherosclerosis in the heart include ischemia,
tissue necrosis or myocardial infarction (MI), unstable angina, acute coronary syndrome
and sudden death, to name a few, all of which are symptoms associated with CAD27.
Typical markers of atherosclerosis include measures that detect downstream effects of
atherosclerosis-mediated inflammation/injury such as plasma high-sensitive C-reactive
protein (hs-CRP)28, interleukin-6 (due to increased level of cytokines) and tumor necrosis
factor-α29. In addition, non-inflammatory markers associated with arterial stiffness such
as aortic pulse wave velocity29,30, ankle-arm index29, arterial (brachial) intima media
thickness31 are also usually used in assessing atherosclerosis risk and burden.
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Figure 1.3: A concise description of the pathogenesis of atherosclerosis

For detailed description consult the following references 17, 25-27.

These markers have been shown to be effective predictors of CAD29.
Interestingly, recent evidence have also shown that the common carotid intima media
thickness (CIMT) can be used as surrogate marker of generalized atherosclerosis 31,32, and
adding CIMT measurements to typical risk predictors can improve 10-year CAD risk
stratification33. Atherosclerosis is not only significant in pathology of CAD but it is
associated with abnormal changes in the structure and function of the brain, and will be
discussed further in section 1.5.

10

1.2.5

Risk factors for coronary artery disease
Age is the most important predictor of atherosclerotic diseases. Other well known

risk factors attributed to CAD are listed in the table 1.134–38. These risk factors are used in
identifying individuals at increased risk for CAD. In Canada, a comprehensive program
for diagnosis and treatment of atherosclerosis disease, and prevention of cardiovascular
disease, based on these risk factors is managed by the Canadian Cardiovascular society34.
It is important to note that these risk factors are also associated with structural and
functional impairments in brains of older adults, as will be discussed further in section
1.5.

Table 1.1: Major Risk Factors for Coronary Artery Disease
Non-modifiable
Age and Gender: Men ≥ 40 years old or women ≥ 50 years old
Genetics: Family history of premature CAD in first-degree relative
Modifiable
Hyperlipidemia : LDL >5.0mmol/L, total cholesterol to HDL ratio > 5
Hypertension: systolic > 140 mmHg or diastolic > 90mm Hg
Diabetes mellitus
Obesity and physical inactivity: increased waist circumference or BMI >27 kg/m2
Evidence of atherosclerosis: hs-CRP > 2.0 mg/L
Smoking
Compiled from references34–38
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1.2.6

Current therapeutic interventions
Interventions for CAD can be classified as either primary therapeutic and/or

secondary preventative interventions. A list of the main current interventions and
promising therapeutic options are listed in table 1.2. The majority of primary
interventions are geared towards improving or restoring coronary blood flow, while
secondary interventions are employed to minimize risks and maintain coronary function.
A number of these interventions have been shown to interact with cerebral blood flow
regulation or transiently affect brain functions such as cognitive processing (table 1.2).

Table 1.2: Interventions employed in management of CAD
Pharmacotherapy :can be both primary and preventative
1. Lipid lowering and thrombolytic therapy
a) Statins:
 Reduction of CAD risk39 by inhibiting hepatic production of cholesterol, thereby
reducing further thickening of vessel wall diameter40,41.
 Reverse endothelial dysfunction in coronary vessels40
 Lower levels of anti-inflammatory markers such as hs-CRP40,41.
 Associated with increase in cerebral blood flow41 and lower risk for vascular
dementia41,42.
b) Anti-inflammatory :
 Include antiplatelets and anticoagulants.
 Inhibit the formation of occlusive thrombus by preventing aggregation of
platelets40.
 A notable example is salicylates such as aspirin.
 The effect on CAD risk management is still unclear40.
 Evidence of less cognitive decline in high-risk CAD patients43 although
contradictory.
2. Nitrates: Mediate release of NO and cause vasodilation, improving coronary blood flow44.

12

3. Antihypertensive
a) Calcium channel blockers :


Used in secondary prevention of CAD45



Cause vasodilation and lower ventricular pressure load45

b) Beta-blockers:


Used in treatment of CAD symptoms including acute coronary syndrome and stable
angina



Block SNS receptors, produce positive inotropic effects (increase myocardial
contractility) and prevent left ventricular dysfunction46.

c) ACE inhibitors:


Reduction of MI and left ventricular dysfunction47.



Blocks angiotensin-converting enzyme (ACE) action in the renin-angiotensinaldosterone system47.



Treatment in hypertensive with ACE inhibitors or similar acting angiotensin receptor
blockers have been associated with less decline in cerebral blood flow over time48
and less decline in cognitive function49.

Coronary revascularization techniques


Includes percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG).



Used in patients with unstable angina or acute MI as primary intervention to reduce the death or
MI50.



Transient memory loss and reduction in psychomotor speed have been reported after first few
weeks of CABG and resolves 1- 3 months after surgery51,52.

Cardiac rehabilitation (CR): secondary prevention programs aimed at minimizing CAD risks
include34,53.
1. Smoking cessation
2. Low sodium and sugar diet
3. Caloric restriction
4. Regular moderate- intensity physical activity and low-impact aerobic exercise (30-60 minutes
most days of the week) 54.
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Prescribed exercise training interventions: combine moderate-to-vigorous intensity aerobic exercise
and resistance training as recommended by the American College of Sports Medicine and American
Heart Association for older adults55.
1. Aerobic exercise: at a frequency of 3-5 days/week and an intensity of 50-80% of exercise capacity
lasting for a duration of 20 - 60 minutes using modalities such as walking, treadmill or cycling
exercises54.
2. Resistance exercise: at a frequency of 2-3 days/week and an intensity of 10-15 repetitions per set
lasting a duration of 1-3 sets of 8-10 different upper and lower body exercises using modalities
that include various forms of weight lifting and strength training54.

Promising future interventions
1. Genomics-based therapy: Molecular targeting of pharmacological agents to pathways associated
with proteins that encode genes important for lipid production, to improve responsiveness. For
instance clopidogrel is an antiplatelet being investigated in patients with genetic variants in
cytochrome P-450, an enzyme required for metabolism of clopidogrel56. In these patients the
antiplatelet effect of the drug is reduced.
2. Stem Cell therapies: preclinical studies and clinical trials are ongoing to determine the benefit of
stem cell therapies in improvement of cardiovascular function by replacement or repair of
damaged cardiac tissue with progenitor cells derived from various embryonic sources57. Clinical
trials have shown some reduction in death and recurrence of MI in stem cell transplants57.
However there are several challenges to this form of therapy including the potential malignant
transformation of the cells57.

Cardiac rehabilitation (CR) programs are central to the management of CAD and
involve multifaceted behavioural modification interventions aimed at reducing the risk of
new MI or recurrence of MI after a coronary event58. In Canada, CR programs are largely
hospital-based with a median duration of 5 months although home-based programs are
also offered as an alternative. Studies have shown that the use of CR led to reductions of
15%58 to 50%59 in mortality rates associated with cardiovascular disease. The core
components of CR include nutritional counselling, risk factors management, psychosocial
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interventions and exercise training54. Moderate intensity exercise training is a key
component of CR programs, and the singular effect of exercise on CAD includes,
reduction in cardiac mortality and morbidity, reduced risk for CAD and increased
myocardial function60. Even, small gains in exercise capacity of 1 ml/kg/min-1peak
oxygen consumption or 1 metabolic equivalent are associated with 10% reduction in
cardiac mortality61. Furthermore there is strong evidence that exercise training can reduce
arterial stiffness in patients with CAD. A review of 5 studies relating exercise training to
arterial stiffness in CAD patients, reported consistent findings of associations of
improved cardiorespiratory fitness and reduced pulse wave velocity and augmentation
index, another measure of arterial stiffness, in CAD patients after completion of exercise
training programmes62. Table 1.3 adapted from the Mayo Clinic proceedings editorial by
Franklin and McCullough63, highlights the therapeutic effects of regular physical activity
on cardiovascular disease. These effect are potentially the results of improved endothelial
function, angiogenesis, proliferation of collateral vessels and regression of coronary
atherosclerosis following repeated bouts of exercise64–66. There is increasing evidence
that suggests that moderate exercise could have neurorehabilitation effects as well.
Section 1.6 will discuss the neuroplastic effects of aerobic exercise training in older
adults, and in adults with increased risks for CAD. In chapters 2 and 3, the potential
capacity of CR-based exercise programs in reversing brain abnormalities observed in
CAD patients are demonstrated.
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Table 1.3: Potential benefits of regular exercise for cardiovascular disease patients.
Anti-atherosclerotic

Antithrombotic

Anti-ischemic

Antiarrhythmic

Improve lipids

↓ Platelet aggregation

↓Myocardial oxygen

↑ Vagal tone

demand
↓Blood pressure

↓ Fibrinogen

↑ Coronary flow

↓ Adrenergic activity

↓Adiposity

↑ Fibrinolysis

↓Endothelial

↑ HR variability

dysfunction
↓ Inflammation

↓ blood viscosity

↑ Nitric oxide release

Adapted from reference63

1.3

Cerebral hemodynamics

Brain perfusion is tightly regulated by several complex mechanisms that ensure
constant supply of oxygenated blood to meet the brain's energy demand. These
mechanisms dynamically adjust cerebral blood flow (CBF) to match changes in neuronal
activity (metabolic regulation), cerebral perfusion pressure (autoregulation), sympathetic
nerve activation (neurogenic regulation) and/or vasoactive factors (chemoreceptor
regulation)

67

. Under normal conditions, the resultant flow (F) is determined by the

differential perfusion pressure (ΔP) and resistance (R) to flow in accordance with
Poiseuille's law68 (Eq. 1):
𝑃1 − 𝑃2 𝜋𝑟 4
∆𝑃
𝐹=
=
8𝜇𝐿
𝑅

(1)

Where P1 is the inflow pressure or mean arterial blood pressure, P2 is outflow pressure or
intracranial pressure which includes central venous pressure and CSF pressure, while r, L
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and µ describe the vessel's resistance to flow and are the radius and length of the vessel,
and the viscosity of the fluid within the vessel, respectively. It follows that CBF is
determined by the difference in cerebral perfusion pressure and cerebrovascular
resistance. Such that alterations to cerebral perfusion pressure or vascular resistance
outside the normal basal range will alter CBF levels and activate regulatory mechanisms
to preserve constant flow. For instance, cerebral autoregulation maintains a relatively
constant CBF over a range of mean arterial pressures from 60 to 150 mm Hg69. If
perfusion pressure drops beyond the lower limit or increases above the upper limit, CBF
will increase or decrease accordingly. All regulatory mechanisms ultimately exert their
influence on vascular smooth muscles of the intracranial arterioles, to increase CBF by
vasodilation or decrease CBF by vasoconstriction. The magnitude of changes in CBF,
and to a lesser extent the corresponding blood volume, is greater during vasodilation than
vasoconstriction70. As such, regional measurements of basal levels of CBF and vascular
resistance of cerebral vessels to a vasodilatory stimuli provide crucial markers of regional
cerebrovascular health71–73.
One of the most potent vasoactive stimuli is CO2. Increased concentration of
blood CO2 increases partial pressure of arterial CO2 (PaCO2) and changes blood tissue
pH, inducing relaxation of vascular smooth muscles directly or via secondary
mechanisms that release vasoactive agents such as prostaglandins and nitric oxide67.
Inhalation of CO2 can trigger changes in pH and vessel diameter within 10s and
subsequent changes in CBF within 30s of the beginning of inhalation, with CBF reaching
peak values around 2 min67. The relative increase in CBF per mm Hg increase in PaCO2 is
around 5%/mm Hg74. This is illustrated in figure 1.4 showing the time courses of end17

tidal CO2 (ETCO2), a surrogate marker of PaCO2, and CBF for a 60-year-old male
inhaling 6% CO2for 5 min.

Figure 1.4: Time courses of CBF and ETCO2 during hypercapnia.

Time courses of ETCO2, total gray matter CBF and breathing rate (BR) measurements in a 60 year old
male acquired every 15s over 13 min. Hypercapnia was induced using 6% CO2+ 21% O2+ 73% N2 for
a duration of 5 min. Time-averaged ETCO2 for normocapnia and hypercania were 37 ± 0.8 and 51 ±
3.8 mm Hg, respectively, corresponding to 37% increase in ETCO2 and 78% increase in CBF relative
to baseline. Breathing rate was maintained at around 15 breaths per minute (BPM) during both capnia
conditions using paced-breathing (metronome) to prevent hyperventilation.

This rapid response of CBF to CO2 makes cerebrovascular CO2 reactivity an
excellent means of probing cerebral hemodynamic alterations. Cerebrovascular CO2
reactivity (CVR) can be described as a measure of the response of the brain's
microvasculature to CO2 stimulus, typically an elevation of arterial CO2 tension (i.e.,
hypercapnia). Hypercapnia manipulations using CO2 inhaled concentrations of 5-8% resulting in an PaCO2 increase of up to 15 mm Hg -are considered safe67 and severe
adverse respiratory, cardiovascular or neurological effects to short-term exposure are
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observed at concentrations ≥10%75. Furthermore, mild hypercapnia manipulations are
low cost, easy to implement, relatively reproducible and highly sensitive to hemodynamic
impairments by 'steal phenomenon', where vessels that are maximally dilated will have
reduced capacity to increase CBF76. However, it should be noted that the acute effect of
mild hypercapnia on brain oxygen metabolism77 and neuronal activity67 is unclear and
being investigated by various groups.

1.4

Brain changes associated with normal aging

Aldred Scott Warthin (1928) described normal aging as a 'syndrome' - a complex
period of retrogression that "consists, therefore, of a combination of organ - and tissue involutions, shown histologically by well-defined tissue-lesions and manifested clinically
by descending function-curves."78 This process he argues, starts gradually after
maturation, develops throughout mid-life, accelerates by age 70 at which time tissue
involutions start to become 'clinically apparent', and terminates in biological or
pathological death78. In the brain, various studies using tissue histology and
morphometric (CT and MRI) techniques, support Warthin's assertion of age-related tissue
involution79. All structures in the brain80, with the exception of the brainstem80–82 undergo
consistent progressive age-related involution80. Decline in total and regional volume have
been reported for gray matter (GM)83 and white matter (WM)79 following maturation
around the age of 30 years old, as well as impaired CBF84–86, cerebral metabolic rates of
glucose (CMRglc)85,87 and oxygen (CMRO2)85,86. The pattern of age-related brain
changes vary across the brain with some regions showing a linear trend, while others
show a non-linear or curvilinear pattern, and some show preservation or delayed age
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effect80,88–90. For instance, the frontal regions particularly the prefrontal, show the earliest
and greatest loss of volume with age79,91, while the hippocampus and cerebral WM show
an initial increase in volume prior to an accelerated decline much later in life80, which
could signify compensation92, while the limbic structures show significant GM
preservation relative to other areas89. This reflects the selective vulnerability of certain
brain regions to aging, and possibly pathological effects79.
It is widely accepted that the topological pattern of normal aging follows an
anterior-to-posterior gradient93, affecting first, regions that mature last during postnatal
brain development89. Myelination, for instance, occurs in the cerebellum prior to the
cerebral lobes and in the occipital prior to the frontal lobes, continuing up to fifth decade
of life94. While loss of myelin sheath have been found predominantly in the anterior
regions of the brain of older subjects compared to younger ones95,96. This 'last-in-first-out'
principle, also referred to as the 'retrogenesis hypothesis'93 is observed in normal aging, as
alterations in GM and WM structure93 and impairments in selective domains of cognitive
function97.This topological pattern of normal aging is what differentiates it from
pathological aging processes such as dementia98–101.The following sections will outline
evidence of age-related retrogenesis in the brain, describe possible neurobiological
contributions to normal brain aging, and outline effects of aging on brain function. It is
important to note that given the large variation in study samples (age range,
exclusion/inclusion criteria, sample size), methodology (i.e. cross-sectional or
longitudinal), image acquisition, and image analysis techniques, comparison of
observations among studies and overall generalization of results are limited.
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Figure 1.5: Illustration of overt age-related brain changes seen on structural MR
images.

T1-weighted images of a young (left, 24 years old male) and older (right, 68 years old male) healthy
participants, illustrates common differences in brain structures typically attributed to normal aging.
Brain atrophy, sulcal widening and enlarged ventricles (shown in red arrows) are evident in the older
brain. Images were derived from data collected as part of my thesis project.

1.4.1

Evidence of age-related changes in the brain
Brain atrophy100, ventricular enlargement102–105 and increase in white matter

hyperintensity91 are overt appearances of normal aging easily detectable in structural MR
images, as exemplified in figure 1.5, in a young and older subject randomly selected from
data acquired during my thesis project. On average, the total GM volume (GMV) decays
by 2-3% per decade105,106, where the frontal lobe being one of the highest, decreases at a
rate of around 5.5% per decade107. Reductions in GMV87,89,90,103,104,108–110 and cortical
thinning93,111,112 related to aging are found more often in the frontal and parietal
regions113, with minimal involvement of the cerebellum82,114, temporal lobe113 and
subcortical regions including the limbic89 structures, and general preservation of the
brainstem81,82 and occipital lobe115.
The hippocampus and entorhinal cortex known for their significance in memory
processing116,117 and vulnerability to Alzheimer's disease (AD), also experience age21

related brain atrophy80,93,100,105,118. However, normal aging of these medial temporal lobe
structures are more subtle compared to the drastic changes seen in AD93. Their volumes
are relatively stable throughout young adult and midlife, after which they decline
exponentially from an annual rate of atrophy of ~0.05% in midlife to ~2% after age 60 93.
For comparison, the annual rate of atrophy reported for MCI and AD subjects in the
hippocampus and entorhinal cortex are 2.39% and 3.64%, respectively93.
Likewise, deficits in WM volume also seem to appear much later in life, after the
age of 70 and decline more rapidly than GMV88,119,120, following similar spatial pattern to
GMV loss119,121. In healthy elderly adults, loss of WM volume is more prominent in
prefrontal regions118,121–123, followed by regions within the parietal cortex118,121 and
inferior temporal regions121,123. Furthermore, the presence of focal areas of increased
signal intensity on T2-weighted MR images, known as white matter hyperintensities
(WMH), are common in deep WM and periventricular WM regions of older adult
brains91,119,124,125. Subcortical and periventricular WMH are prevalent after the age of 60
years, occurring in nearly 90% and over 60% of individuals, respectively124,125. Although,
the severity and extent of WMH lesions are associated with increased age124, and linked
to cognitive impairments in memory125,126 and processing speed126,127, the increased risks
for vascular disease associated with aging such as hypertension, are greater indicators of
WMH than aging alone125.
On the other hand, results of WM microstructural integrity assessed using MRI
measurement of WM diffusivity, such as diffusion tensor imaging (DTI), offer more
consistent findings of age differences in WM119 and provide better support of the
retrogenesis hypothesis91,119. Diffusion-weighted indices including fractional anisotropy
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(FA), radial diffusivity and axial diffusivity have been used in numerous studies to
quantify white matter structural integrity during brain development, normal aging, and in
various disease states128–130. Reductions in FA could signify degradation of WM
structure, inflammation, or loss of glial cells, while increased radial and axial diffusivities
suggests demyelination and axonal loss or damage128–130. Decreased FA in older adults
compared to younger adults have been reported primarily in anterior WM including
unicinate fasciculus bundles of frontal WM, cingulum bundle in parietal, WM tracts in
anterior portion of temporal lobe, but not in the inferior longitudinal fasciculus of the
posterior temporal lobe connecting to the occipital101,131–136. Increased radial and axial
diffusivities have also been found in the anterior portion of the corpus callosum
(genu)134,135,137. Hasan et al. measured diffusivity in 24 WM fiber tracts in 119 healthy
subjects from 6 to 68 years old and demonstrated a U-curve relationship between
increasing age and radial diffusivity138. An initial decline in diffusivity was observed
post-adolescence up to the age of 40, which the authors suggested was reflective of
sustained "progressive" myelination, followed by rapid increase in diffusivity with
advancing age, which was attributed to "regressive" and "degenerative" natural aging138.
A similar but inverted U-curve was also observed in tracts measured by FA138.These
diffusion-weighted MRI observations are supported by histological examinations that
have shown myelin and axonal loss in various areas of the brains after midlife, in both
human95,96,139 and animal140 studies. When taken together, measurements of WM macroand micro-structure suggest that brain regions with recent myelination following
maturation are more prone to age-related myelin degeneration.
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Similar to GM and WM structural deficits, an anterior-to-posterior gradient in
GM hypoperfusion have be found with advancing age8,9,86,137,141–145, starting as early as
20 years old and progressing steadily through middle and old age8,9,84,86,146, at an annual
global rate of nearly -0.4%137,143,144.The greatest association with normal aging, were
found in the frontal and parietal lobes, followed by the temporal cortex, while minimal
relative changes are seen in the occipital or portions of the cerebellum8,9,86,137,141–144,147,
even after correction for signal dilution from partial volume effects137,142,143. These agerelated changes in GM CBF are usually independent of underlying brain atrophy or
cortical thinning143, suggesting that separate neurobiological mechanisms could mediate
brain atrophy and cortical hypoperfusion, such as vascular aging23,148. Aging affects not
only resting GM CBF, it can impair the brain's ability to respond rapidly to an increase in
task-demand9,86,149,150.

This

is

evident

in

reduced

CVR86,149–151,

decreased

CMRglc85,87,145,147,152, and in increased oxygen extraction85,86 with advanced age. Lu et al
demonstrated that age-related decline in CVR observed in the prefrontal cortex, appeared
earlier and at a much greater rate of decay compared to CBF86. These age-related
impairments in cerebrovascular hemodynamics and in metabolism of brain energy
substrates could explain associations of aging to cognitive decline in domains of memory
and attention153–155. However, age-related changes in CBF, CVR or CMRglc are
controversial given that some studies have reported no change156–158 (after partial volume
correction)159,160, or an increase8 with increase in age. Investigations of subtle change in
CBF or CMRglc related to aging are largely limited by the ability of current imaging
techniques to spatially resolve GM/WM-specific voxel signals and minimize partial
volume effects161,162. In general, structural and functional brain changes associated with
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normal aging are likely restricted to anterior portions of brain, areas that are involved in
memory, executive functioning and attention.

1.4.2

Neurobiology of normal brain aging
The neurobiological processes that mediate the structural and functional changes

associated with age are not fully understood. Aldred Scott Warthin (1928) postulated that
age-related changes are "…due to a loss of growth-energy, so that the cell loss exceeds
the regenerative powers, and numerical and quantitative atrophies ensue."78 This speaks
not only to changes in the brain’s energy demand and supply with age85, but also to the
restorative or plastic capacity of the brain following age-related tissue involution163, as
will be described in section 1.6. Earlier propositions suggested that normal brain aging
was likely a result of neuronal loss94,95,164 secondary to cerebral hypoperfusion141,165 and
subsequent hypometabolism166. However, recent evidence demonstrates that normal brain
aging is more likely to arise from loss of dendrites (spine and aborization), decrease in
synaptic pruning and alterations in neurotransmitter response over time as the brain
struggles to maintain energy demands in the face of shrinking supply (for review see
Dickstein et al167). Significant reductions in synaptic density and the number of synapses
have been reported in the prefrontal168–170, superior temporal and precentral cortices170,171
in older humans compared to young, and in aged nonhuman primates172,173, canines174
and rats175. In addition, age-related reductions in glutamatergic176, serotonergic177 and
cholinergic178neuroreceptor density and binding sites of frontal regions, along with
reductions in myelination95,96, contribute to disruptions in brain signalling pathways167,
which are observed as alterations in functional connectivity of frontal networks such as
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the default mode network179–183. Furthermore, molecular and microvascular changes
associated with aging including, increased oxidative stress, atherosclerotic plaque
formation, vessel stiffness, increased arterial blood pressure, inflammation and decreased
capillary diameter and density, contribute to the attenuation of resting CBF, and create
impairments in cerebrovascular tone23,148, further limiting the brain's ability to meet
energy demands in task-intensive regions such as in the frontal cortex.

1.4.3

Effect of age on brain function
The cumulative effect of various changes in brain structure, metabolism and

cerebrovascular function resulting from normal aging can impact the performance of
cognitive function184,185. Poorer performance on tests for verbal fluency, visuospatial
function, working memory, executive function and selective attention are associated with
increased age186,187. Although brain regions (prefrontal, medial temporal and parietal)
negatively associated with aging are also associated with cognitive control, evidence
correlating cognitive decline to structural and functional decline in the these brain regions
is limited188. Recent meta-analyses of 80 studies, in which brain activity was measured in
young and old healthy adults during performance of cognitive tasks, provide a clearer
understanding of the brain's response to normal aging189,190. Both reviews point to the
compensatory mechanisms employed by the brain of older adults when engaged in
cognitive processing189,190, which could be through modes of bilateral prefrontal cortex
activation (i.e. Hemispheric Asymmetry Reduction in OLDer Adults, HAROLD) or a
combined increase in anterior brain activity and decrease in posterior regions (i.e.
Posterior-Anterior Shift in Aging, PASA)185. Compared to young adults, older adults
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have increased activity largely in the prefrontal cortex, less activity in the occipital during
perceptual tasks and no difference in the parietal lobe, even when performance was equal
between groups190. In addition, older adults that performed better tend to have an increase
in the left prefrontal activity while those who performed poorly activated only the right
prefrontal190. These patterns of cognitive activation in old adults support views of
increased recruitment of brain resources (HAROLD or PASA) during demanding tasks to
maintain normal performance in the presence of structural and functional deficits185,189. It
remains to be seen if over-recruitment of frontal regions in older adults is indicative of
successful cognitive aging or a mark of inefficient activation of specialized brain
networks (dedifferentiation)185. It is quite possible that compensatory activations are
attempts at re-organizing frontal brain networks that are structurally191 and functionally192
altered during aging.

1.5
Brain changes associated with CAD and increased
risk for CAD
"The secondary pathologic conditions that are made possible and favoured by
primary involution process are many and of great clinical importance, because it is
usually through some one of these that the senile individual is kept from achieving a
biological death. They fall into several well-defined group: 1) secondary to vascular
changes...."A S Warthin, 192878.
The decline in regional brain structure and function in older adults with risks
factors for CAD is greater than the decline attributed to normal aging6, often affecting
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posterior brain regions and cognitive domains that are relatively stable during normal
aging. A systematic review of neuroimaging findings from 77 studies that investigated
brain changes related to CAD risk factors in asymptomatic individuals, concluded that
risk factors of hypertension, type II diabetes, obesity and hyperlipidemia, independently
contribute to adverse changes in the structure and function of the brain6. More
importantly, an increase in the number of risk factors appears to increase the magnitude
of brain changes6. The impact of CAD risk factors appear to be more regional than
global6. In this section, evidence of regional brain atrophy, impaired hemodynamics and
abnormal brain metabolism related to CAD and disease risk factors will be briefly
presented.

1.5.1

Changes in brain structure
Regional brain atrophy in the frontal, temporal and parietal gyri are associated

with hypertension193,194, type II diabetes195–197 and obesity6. A voxel-based morphometry
(VBM) study of 478 adults aged 60-64 years found an association between hypertension
and decreased GMV in the medial frontal, superior frontal and superior temporal regions
of male subjects, after controlling for effects of age and other vascular disease risk
factors194. In another study of 134 adults from 50-70 years old, higher systolic blood
pressure was associated with decrease in GMV in the supplementary motor area, superior
frontal gyrus, anterior cingulate and middle temporal regions in male subjects193. No
association between hypertension and brain volume were found among women subjects
in both studies. Novak et al197 and Last et al195 reported lower GMV in the parietal and
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occipital lobes of type II diabetics compared to non-diabetics, and more recently a VBM
study198 found decreased GMV in the temporal and precentral gyri as well.
An increase in white matter lesions and a decrease in regional WM volume are
associated with hypertension199–202and diabetes195,197,198,200,203. Ventricular widening have
also been observed in hypertensive204,205 and diabetic206 patients compared to agematched controls. Even in earlier on in life, higher systolic blood pressure have been
linked to white matter injury and decreased regional GMV in individuals under the age of
50207. However, it appears that higher systolic blood pressure may not be associated with
longitudinal changes in brain volume199,208 or in the frequency and severity of white
matter lesions200,202,203. Rather, higher diastolic blood pressure in midlife are linked to
greater longitudinal decline in GMV208 and increased frequency and severity of white
matter lesions200,202.

1.5.2

Changes in brain function
Individuals with uncontrolled or untreated hypertension have been shown to have

regional hypoperfusion in the superior, inferior209 or and orbito-frontal cortices, anterior
cingulate, and temporal and occipital regions compared to normotensive controls210–213.
Accelerated decline in regional CBF over time has also been observed in hypertensive
adults compared to older normotensive adults211 and could be linked to uncontrolled
increases in blood pressure48 and increased arterial stiffness209,214. One study of type II
diabetics reported reductions in CBF under resting conditions and during hypercapnia in
the temporal and parieto-occipital regions. Although in the diabetic group, hypertension
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was associated with lower CBF including during hypercapnia195. Another recent study in
a larger cohort (541) of middle aged adults, found lower CVR in the cingulate and medial
prefrontal lobe in individuals with elevated blood pressure compared to normotensive
subjects, but no difference in regional CVR in individuals with elevated blood glucose or
blood cholesterol compared to subjects with normal levels73. Hypertension is also
associated with significant reductions in CMRglc in the striatum215 and with increased
insulin resistance in the frontal, cingulate, parietal and temporal lobes216.
This abnormality in glucose metabolism in diabetics was linked to poor
performance on memory tasks and an activation pattern that seem to demonstrate
compensatory attempts during delayed recall tests216. Impairments in memory as well as
in executive control, psychomotor speed and attention are reported in hypertensive
adults193,199,204,212 and in individuals diagnosed with cardiovascular disease217,218. In
cardiovascular disease patients, one study demonstrated accelerated decline over time in
visuospatial skills, memory and overall cognitive function, and a linear decline in
language, attention and psychomotor speed217. It is quite possible that cognitive
dysfunctions associated with vascular disease are related to cerebral hypoperfusion and
abnormal distribution of CBF during increased demand. For instance, in hypertensive
subjects, decreased CBF in the superior frontal, anterior parietal and temporal was
associated with decreased performance in attention and psychomotor processing212. In
addition, during working memory tasks, hypertensive compared to normotensive subjects
had lower increase in posterior parietal CBF219, displayed attempts at recruitment of other
cortical regions, and increased contralateral flow220. These regional flow alterations could
be mediated by vascular aging that are exacerbated by cardiovascular disease. Cerebral
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hypoperfusion is linked to increased arterial stiffness221, and increased evidence of
atherosclerosis214, and is associated with comprised neuronal viability222. In addition,
higher carotid intima media thickness and increased pulse wave velocity are linked to
poorer memory performance and lower scores on processing speed and executive
function218,223. However, the pathogenesis of brain alterations associated with
cardiovascular disease and disease risk factor are not well known. Equally, it is unclear
what impact cardiovascular disease, specifically diseases of atherosclerotic origin such as
CAD; have on the structural integrity and functional capacity of aging brains.

1.6
The potential neuroplastic effects of aerobic
exercise training
1.6.1

Defining physical fitness training
Physical activity contributes to lower risk for CAD53and improves brain health

even in late adulthood and in chronic sedentary individuals224. Physical activity can be
defined as movements of the body produced by skeletal muscles that results in
expenditure of energy225. Physical exercise is purposeful physical activity that is planned
and repetitive225. While, physical fitness "is a set of attributes that people have or
achieve" (Caspersen et al225, page 128) and can be defined as "the ability to carry out
daily tasks with vigor and alertness, without undue fatigue and with ample energy to
enjoy leisure-time pursuits and to meet unforeseen emergencies" (Caspersen et al225, page
128). Cardiorespiratory fitness is a health-related component of physical fitness defined
as the ability of the circulatory and respiratory systems to supply oxygen during sustained
physical activity225. Individual exercise capacity and fitness level are determined
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primarily by age, sex, exercise habit and cardiovascular health status226. Capacity and
fitness level are measured using graded exercise tests such as treadmill or cycle
ergometer, in absolute terms as metabolic equivalent of tasks (METs) meaning the
amount of oxygen consumed at rest, where 1 METs approximates 3.5 mL of oxygen per
kilogram of body weight per minute226. However, the gold standard measure of exercise
capacity and fitness is the relative measurement of maximal oxygen consumption
(VO2max) during dynamic exercise, a level where the greatest amount of oxygen is
consumed despite an increasing workload226. For example, normal VO2max of a 50-59
year old male is roughly 36 mL/kg/min or 10 METs226. The amount of VO2max in
healthy humans is governed largely by the amount of systemic oxygen delivery to
skeletal muscles, which is in turn, determined by the maximal cardiac output227.
The recommended form of physical fitness in older adults and adults with
cardiovascular disease are moderate-to-vigorous intensity aerobic exercise and musclestrength training activities55. In absolute and relative terms, moderate-to-vigorous
intensity exercises are between 3 to 6 METs55 or 50 to 80% of VO2max55 or a score of
12-16 on the 20-scale Borg rating scale of relative perceived exertion226. An
improvement in cardiorespiratory fitness by 5.4 ± 1.2 ml/kg/min61 or an increase of 15 to
20%228 in peak oxygen consumption can be expected by cardiac patients enrolled in CR
programs. However, perceived improvements in fitness level reported in various studies
are difficult to compare, limited by heterogeneities in training intensities (low-moderate,
vs. moderate-high), programme duration (4 -52 weeks), number of exercise sessions (36
or > 36 sessions), exercise modalities (aerobic vs. mixed of aerobics and strength
training), patient fitness level on entry and modality of fitness testing (maximal treadmill
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or cycle ergometer vs. predictive submaximal testing including modified treadmill tests,
or 1-mile track walk test vs. self-reported physical activity questionnaires).These
variations in aerobic training regimen and fitness testing also limit comparisons of
neurovascular benefits associated with aerobic exercise training. In general,
improvements are associated with higher exercise intensity and with programs consisting
of 36 or more sessions of aerobic-based exercise or a combination of aerobic and
resistance training61. Majority of the gains in cardiorespiratory fitness are achieved in the
first 4-12 weeks of training and little or no further increase are observed after initial
gain61. Submaximal testing using graded exercise protocols with shorter stages and
smaller transitions between workloads are preferred for testing fitness level in cardiac
disease patients226.

1.6.2

Effects of moderate intensity aerobic fitness training on
brains of older adults
A review of studies examining the relationship between physical activity and

brain volume in older adults outlined 9 studies where higher fitness level was associated
with greater gray matter volumes in the anterior cingulate cortex, prefrontal, parietal and
temporal regions, as well as the hippocampus224,229. Notably, Colcombe et al (2003)230
showed that age-related decline in the prefrontal, parietal and temporal gray and white
matter regions were moderated by higher aerobic fitness level. Compared to other brain
areas, these regions also showed greater tissue preservation with increasing fitness
level230, consistent with findings from other studies224,229. It appears that regions that
show the greatest rate of age-related decline in brain volume discussed earlier are also the
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regions that are highly plastic and respond more readily to modifying effects of exercise.
In the hippocampus, for instance, a study found an annual increase in volume of 2% in
the anterior hippocampus of aerobically trained older adults compared to an annual
decline of 1.5% in a stretching-toning control group231.The increase in volume was
associated with increased levels of serum brain-derived neurotrophic factor (BDNF) and
improved performance in spatial memory tasks231. In another study, peak VO2 was
positively associated with fractional anisotropy in the middle and posterior cingulum
bundle232 and with fractional anisotropy and radial diffusivity in the body and genu of the
corpus callosum233 of brains of previously sedentary older adults.
Likewise, increases in CBF have been found in the hippocampus234, anterior
cingulate cortex235 and posterior cingulate/precuneus236 of aerobically trained older
adults. Four months of aerobic exercise showed increased connectivity between the
hippocampus and anterior cingulate cortex in the trained group compared to healthy
controls234. Increased brain network connectivity and improved network efficiency
between fronto-temporal regions and within the default mode network and frontal
executive networks are also demonstrated in aerobically trained older adults237. In
addition, positive correlation between aerobic fitness and task-induced activation in the
anterior cingulate, lateral prefrontal and lateral parietal regions are evident across various
tasks for executive function and semantic memory retrieval, potentially mediated by
increased regional brain volume229. However, Colcombe et al238 reported decreased
activity in the anterior cingulate, left medial frontal and middle superior temporal in
aerobically trained older adults performing conflicting response tasks, a probe of the
attention-driven network. This finding was attributed to improved adaptations in the
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attention network following exercise training238. It is quite clear that most domains of
cognitive control in healthy older adults benefit from physical activity, with the greatest
improvements seen in domains of executive function, while modest improvements are
seen on tasks of attention and spatial memory, and limited effect on tasks for working
memory214.
In cardiovascular disease, 12-to-18 weeks of cardiac rehabilitation were
associated with improved performance on executive function, psychomotor speed,
attention and episodic memory tasks, and these improvements were preserved for up to 9
months after completion of a 12-week CR program239. Although, there is overwhelming
evidence of the neuro-protective and neuroplastic effects of aerobic exercise in healthy
older adults, the benefits of aerobic exercise, alone or as part of a CR program on brain
structure and function in cardiovascular disease patients are not well known. In fact, only
one study to date has linked aerobic exercise-based CR programs to regional changes in
CBF and GMV in brains of cardiovascular disease patients. In that study, MacIntosh et
al240, associated gains in fitness level (VO2 peak) after 6-month CR program with
baseline CBF in the left postcentral gyrus and baseline GM density in the right putamen.
The effects of exercise training were not explicitly investigated. This highlights the need
for research to investigate the neuroplastic efficacy of exercise-based CR programs.
It is not surprising that exercise can modify regional brain structure and cause
selective changes in function as well. A number of studies have shown that skill training
and learning modify structures within the adult brain241. Learning-induced plasticity, for
instance, has been shown in the occipto-temporal cortex of individuals trained to
juggle242. London taxi drivers were found to have larger posterior hippocampus volume
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compared to controls and the enlargement was correlated to length of time spent driving a
taxi cab, demonstrating the effect of navigational skill experience243. Interestingly, the
effects of exercise are not only limited to motor areas, but also effects are significant in
cognitive regions of the brain, signifying the potential salutary effects of exercise training
in remedying pathological brain aging. It can be said that aerobic exercise training could
potentially offer long-term neuroprotective benefits. This was demonstrated in a recent
study where walking 72 blocks per week, equivalent to 9-15 km per week, was associated
with greater GM volume in the inferior frontal, hippocampus and supplementary motor
area nine years after exercise cessation244, and a reduced risk for developing cognitive
impairments244. Meta-analyses of exercise training in older adults concluded that shortterm exercise training when used as an intervention, offered cognitive benefits in
individuals with dementia or cognitive impairments245 but not in older adults free from
cognitive impairments246. In all, moderate intensity aerobic exercise is sufficient to elicit
significant changes in the structure and function of the adult brain224.

1.6.3

Plausible neurobiological mechanisms
The neurobiological mechanisms of exercise-induced neuroplasticity or influence

of exercise on cognition are unclear. Animal studies points to neurogenesis, angiogenesis,
synaptic plasticity and upregulation of neurotrophins247 as possible neurobiological
mechanisms. Rodent studies have shown that animals exposed to voluntary running have
increased number of new neurons, spine density and higher levels of neurotophin in the
hippocampus compared to sedentary controls, which translated into enhanced learning
and memory for Morris water maze tasks and improved performance on avoidance
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tasks247. It is more likely that exercise induces synaptogenesis rather than neurogenesis or
true increase in neuronal volume241. Increased GM volumes observed post exercise
training are likely due to expansion of the soma and nucleus of neurons and gilal cells as
well as increased synaptic density, dendritic branching and dendrite spine proliferation241.
These microstructural changes are potentially mediated by upregulation of neurotrophins
that stimulate cell turnover and neuron proliferation including signal proteins such as
BDNF, vascular endothelial growth factor (VEGF) and insulin-like growth factor 1 (IGF1)247. Increased concentration and expression of BDNF in the hippocampus, frontal
cortex, striatum and cerebellum after exercise training have been observed in mice

248

.

When BDNF binding is blocked in mice performing water maze tasks, the effect of
exercise is abolished249. Higher serum concentration of BDNF as a function of short-term
exercise have been observed in a few studies of young adults250. Increased serum levels
of BDNF have been observed in older adults after 1 year of exercise training and was
associated with increased hippocampal volume231. However, there is no clear indication
that high-intensity exercise or long-term chronic exercise have positive effects on BDNF
levels250.
A more immediate effect of exercise is angiogenesis. Exercise is associated with
proliferation of new vessels and increase expression of signal proteins such as VEGF and
IGF-1 involved in production of new vessels. Exercise-induced increases in capillary
density and VEGF transcription have been observed in the motor cortex, hippocampus,
striatum and substantia nigra of mice brains163. Using magnetic resonance angiography,
Bullitt et al251 demonstrated that highly fit healthy older adults had an increased number
of small vessels compared to low fit individuals. Another recent study found increased
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cerebral blood volume (CBV) in the dentate gyrus of the hippocampus of young-tomiddle-aged adults after 3months of exercise training252. Individuals with higher VO2max
had higher dentate gyrus CBV, but no change in performance of verbal learning (all-trial)
or delayed recall memory tests252. These observations corroborated observations of
increased CBV in dentate gyrus of adult mice that performed 2 weeks of voluntary wheel
running compared to non-exercising controls252. Subsequent post-mortem studies found
positive correlation between CBV and bromodeoxyuridine, a marker of newly born cells,
in the dentate gyrus252.
In general, there is substantial evidence supporting the notion of exercise-induced
proliferation of neuronal cells and increased capillary density, synaptic density and
expression of neurotrophic factors, all of which contribute to enhanced structural integrity
and improved brain network connectivity/function.

1.7

Quantification of regional brain changes using MRI

This section describes the brain imaging techniques used in this thesis to measure
differences in regional brain structure and function between coronary artery disease
patients and age-matched controls. Regional differences in brain structure were measured
on a voxel-by-voxel basis as local differences in gray matter density using a voxel-based
morphometry (VBM) approach implemented in the Statistical Parametric Mapping
(SPM) software (http://www.fil.ion.ucl.ac.uk/spm/software/spm8/), which is described in
the first portion of this section. Next, arterial spin labelling (ASL), a non-invasive
perfusion MRI technique for assessment of regional differences in CBF and CVR, is
discussed. The last portion of this section presents the rationale for the use of ASL-based
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hemodynamic measures as suitable substitutes for established markers of brain function
such as glucose metabolism, and introduces a study performed to investigate the regional
correlation of CBF to cerebral glucose metabolism, which is described in detail in chapter
4.

1.7.1

VBM measurements of gray matter volume changes
VBM is an automated technique for brain segmentation and voxel-by-voxel

comparison of local tissue (typically gray matter) concentration/volume between groups
of subjects or against a known parameter of interest. It has been widely used in studies of
brain atrophy in normal aging90 and neurodegenerative conditions253, as well as in
investigations of neuroplasticity224. Data for VBM analysis are typically high-resolution
(1-mm isotropic) three-dimensional T1-weighted anatomical MR images. T1-weighted
imaging, which refers to sensitizing MR pulse sequences to the longitudinal relaxation
time of water, is used as it is one of the primary means of generating MR contrast in
different tissue types. In brain, good soft tissue contrast is achieved because of
differences in the T1 values of GM, WM and CSF, which enables classification of the
signal intensities of the various tissue types in each voxel. At a magnetic field strength of
3T, the T1 values of GM, WM and CSF are 1445 ± 119, 791 ± 27, and 4163 ± 263 ms,
respectively254.
At the basic level, VBM involves the registration of individual T1-weighted
images to a common space or template, an approach known as spatial normalization,
followed by segmentation into GM, WM and CSF tissue classes, and spatial smoothing
of GM segments prior to voxel-wise statistical analysis255. The optimized VBM method
available in SPM8 employs additional preprocessing steps to exclude non-brain voxels
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prior to spatial normalization and subsequent segmentation108. It also provides options for
computing GM volumes by scaling the voxel concentration by the amount of deformation
estimated during spatial normalization, a process known as modulation108. Modulation
compensates for the non-linear effect of spatial normalization and preserves the total
amount of GM signal in the normalized data108. An extension of the optimized approach
includes GM/WM templates generation for spatial normalization, by iterative averaging
all subjects data using the DARTEL tool (diffeomorphic anatomical registration using
exponentiated Lie)256.
In SPM, image segmentation is based on a modified mixture of Gaussians where
tissue classes (GM, WM or CSF) are modeled by Gaussian distributions of signal
intensities combined with a priori knowledge of the spatial distribution of different
tissues in normal subjects, derived from probability maps257. With this approach, each
voxel is assigned a particular tissue class based on the maximum likelihood of belonging
to that class. Essentially, the segmentation step generates images where each voxel has a
posteriori probability ranging from 0 to 1. The GM/WM spatial priors are either the
default priors derived from a standard template (ICBM-152 template, Montreal
Neurological Institute) or study-specific, generated from averaged data of all subjects in
the study using DARTEL256. The default method for spatial normalization in SPM
registers T1 images to a standard template by minimizing the residual sum of squared
differences between the images and the template using a 12-parameter affine
transformation258. Normalization via DARTEL is highly recommended as this increases
the accuracy of inter-subject alignment259, especially for older brains where atrophy can
bias matching of T1 images to standard template260. In general, SPM provides a complete

40

and efficient package for measuring macroscopic differences in GM volume across brain
regions, including generation of individual GM volumes, inter-subject alignment to a
common space and voxel-by-voxel statistical analysis using general linear models. The
optimized VBM approach as implemented in SPM8 was used in this thesis for
measurement of GM volume differences. This approach is described in detail in section
A1 of the appendix.

1.7.2

Measuring cerebrovascular hemodynamics
The standard tool for assessments of CBF and CVR routinely in clinical practice

is transcranial Doppler ultrasonography (TCD). However, TCD measures CBF velocity
in large vessels, usually the middle cerebral artery, and equates blood velocity to CBF
since the diameter of the vessel is thought to remain constant during vasoactive
stimulation261. Recently, Coverdale et al70 demonstrated that during hypercapnia, the
diameter of the middle cerebral artery can dilate by up to 16%, essentially
underestimating CBF changes by 25%261. In addition, TCD can only provide a global
index of changes in CBF velocity, rather than an assessment of regional CBF changes. In
contrast to TCD, ASL measures CBF directly and can provide images across the whole
brain262. Subsequent assessment of regional CVR can also be made, generally measured
as the ratio of the change in CBF to the corresponding change in ETCO267. Figure 1.6
illustrates typical images of CVR and CBF obtained from ASL imaging from a subject.
Hypercapnia was induced by inhaling 6% CO2 mixed in air for 5 min. However, ASL has
inherent spatial resolution limitations that can affect regional mapping of hemodynamic
changes at a voxel level. An alternative is BOLD functional MRI, which not only has
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higher spatial resolution than ASL but also greater signal-to-noise ratio (SNR)263.
However, the BOLD signal depends on multiple physiological parameters, CBF, CMRO2
and CBV, which can be a confounder263. In addition, BOLD does not follow a linear
relationship with ETCO2262, unlike ASL (CBF), which only becomes nonlinear when
ETCO2 falls within a hypocapnic range262,264.
Figure 1.6: Axial images of CBF and CVR in a single subject.

Axial images of CBF at normocanpia (top row), hypercapnia (middle row) and CVR (bottom row)
across 5 slices in the brain in a single subject. CBF and CVR measures were derived from ASL
imaging265.

1.7.2.1

An overview of ASL

Arterial spin labelling (ASL) is an MRI technique that provides the ability to
measure CBF by manipulating the longitudinal magnetization of endogenous arterial
blood water266. ASL is akin to PET-H215O

267

, the gold standard for CBF measurement,

since both techniques use water as a flow tracer. For ASL, the flow signal is generated
using RF pulses to invert ('label') the longitudinal magnetization of inflowing blood water
protons in arteries. The labelled blood water flows into brain tissue, where it alters the
local magnetization, resulting in a signal change that is proportional to CBF. A flow-
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weighted (ΔM) image is generated by subtracting the labelled image from a control
image, which removes signal contributions from ‘static’ brain magnetization (figure 1.7).

Figure 1.7: Continuous ASL label and control conditions.

Perfusion-weighted (ΔM) ASL image is the difference between label images, in which the
longitudinal magnetization of arterial blood is inverted, and control images in which the magnetization
of arterial blood is fully relaxed.

Because of the direct relationship between CBF and signal change, higher flow values
will result in greater signal changes in the labelled image compared to the control image.
However, due to the rapid loss of T1 label – blood T1 is approximately 1650 ms at 3T 266
– the ASL signal decays rapidly. On the one hand, this enables serial imaging of CBF
with temporal resolution of 5-10s, which is sufficient for capturing dynamic changes in
CBF. On the other hand, the in-flow of labelled arterial blood only reduces the brain
signal by approximately 1% and, therefore, multiple repetitions of label and control
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images are acquired to improve SNR. Accurate CBF measurements are dependent on a
number of factors including the time for labeled water to reach brain tissue, which is
known as the arterial transit time, and labelling efficiency, which refers to the fraction of
water magnetization that is inverted during the labelling procedure. These factors are
discussed in the following section.
There are two main types of ASL labeling approaches, pulsed268 and
continuous269. Pulsed ASL (PASL) inverts the magnetization of a large volume of
inflowing arterial blood using a single short (5-10 ms) RF pulse, as such PASL has better
temporal resolution and labeling efficiency, but poor SNR. Continuous ASL (CASL)
employs long (1-3 s) RF pulses to invert inflowing spins at a single labeling plane. This
increases SNR, but due to continuous RF pulse generation, CASL can deposit relatively
high RF power into brain tissues. To combine the SNR of CASL and labeling efficiency
of PASL with standard transmission RF body-coils available on all commercial MR
scanners, a pseudo-continuous ASL (pCASL)270 approach was introduced. With pCASL,
the long continuous RF pulse of CASL is replaced by a train of short RF pulses that
mimic the adiabatic flow condition of traditional CASL, while minimizing magnetization
transfer effects that cause large subtraction errors between the label and control
conditions. The advantage of pCASL is it provides whole-brain coverage without the
need for an additional labelling coil for CASL or the loss of labeling efficiencies typical
of older labeling approach such as amplitude-modulated CASL271. A recent white paper
on the implementation of ASL for clinical applications recommended the quantification
of CBF using a simplified one-compartment flow model with pCASL imaging266.
Tancredi et al272 demonstrated that the use of pCASL can provide more robust depiction
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of the brain's response to hypercapnia, compared to PASL. A pCASL sequence273 was
used to measure CBF in the studies described in chapters 3 and 4.

1.7.2.2

Quantification of CBF using ASL

CBF in each voxel of pCASL images can be calculated using the standard single
compartment tracer kinetic model as outlined in equation(2) 273.
𝜔

𝐶𝐵𝐹(𝑚𝑙/100𝑔/𝑚𝑖𝑛) =
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,

(2)

where Δ M is the perfusion-weighted signal, M0 is the equilibrium magnetization, which
can be obtained from the control images or by acquiring a separate image with no
longitudinal relaxation effects and label condition. λ is the blood/tissue water partition
coefficient (0.9 g/mL266), α is the labelling efficiency (85% for pCASL274 multiplied by
94% for background suppression),τ is the label duration, and T1b is the T1 of blood
(~1650 ms at 3T)266. The final parameter, ω, is the post labelling delay (PLD), which
refers to the time between the end of labeling period and image acquisition. It is included
to enable all of the labeled water to reach the imaging volume, which minimizes the
effects of arterial transit times275. This simplified model is based on the assumption that
at the time of imaging the labelled water spins remains predominately in the
microvasculature and decays with the T1 of blood266.
Although, the simplified one compartment model provides CBF values that
correlate well with PET-H215O measurements267, the model assumptions are not likely to
be strictly true266. For instance, water exchange between blood and tissue in the capillary
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bed is not quite instantaneous, rather water permeability is limited by the tight junctions
of the blood-brain barrier276. However, because the T1 values of blood and grey matter
are similar at 3T, water exchange effects have minimal effects on the ASL signal 273,276,
and the general view of the one-compartment model is that inherent errors from model
assumptions are relatively small266.

1.7.2.3

Minimizing pCASL-CBF quantification errors

The accuracy of ASL CBF measurements can be degraded by a number of factors,
of which the most important is the arterial transit time. For brain, transit times are usually
between 1 to 2s

266

and vary across brain regions. For instance, the longest transit times

are found in WM, the occipital lobe and vascular border zones277. Transit times are
affected by blood velocity, age, sex, and cerebrovascular disease, and prolonged times are
associated with aging266 and disease278. Individual transit times can be measured by
continuous sampling of inflowing blood using multiple inversions times278 or application
of flow-sensitive spoiler gradients to separate vascular and tissue signal components, as
implemented in the FEAST (flow encoding arterial spin tagging) technique273. However
these efforts are time consuming and in most cases require separate CBF and transit time
imaging. Alternatively, a PLD long enough to allow the entire tracer to reach the imaging
plane negates the need for transit time mapping. The chosen value is set empirically
based on the expected range of transit times within a population and SNR considerations.
In older adults and individuals with prolonged transit times, such as in cerebrovascular
disease, a PLD of 2s is recommended266.
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Measurable errors in CBF quantification can also be attributed to inaccurate label
efficiency and blood T1 values. Label efficiency can be affected by flow velocity, RF
field inhomogeneity, transit time279, and vessel geometry280. Blood T1 is dependent on
hematocrit, temperature and blood oxygenation level, and varies with age and sex 281.
Label efficiency and blood T1 can be measured on each individual subject to minimize
their effects275. Phase-contrast MRI can be used to measure global CBF and compared to
whole-brain CBF values from ASL to estimate label efficiency279. Efficiency can be
optimized if the labeling plane is kept at a distance of ~9 cm279 distal to the anterior
commissural-posterior commissural line and slightly angled for high flow velocities (>
55cm/s)280,282. Subject-specific blood T1 values can be obtained using a inversionrecovery steady-state free precession MR imaging sequence to measure the T1 of venous
blood281.
The SNR can be improved using techniques such as background suppression and
retrospective correction of head motion to reduce physiological noise contributions.
Background suppression involves the use of inversion pulses during PLD to suppress
static brain tissue and intravascular signals. Background suppression has been shown to
increase temporal SNR by up to 75%283 but induces a slight attenuation of ASL signal.
Better SNR can also be acquired using newer fast readout approaches. ASL imaging is
typically performed with multislice 2D echo-planar imaging (EPI) imaging; however, 3dimensional gradient-and-spin-echo (3D GRASE) imaging284 has been shown to improve
the SNR by nearly 3 times283. As such, 3D GRASE pCASL images can be acquired with
less averaging, ergo shorter acquisition times. However, 3D GRASE sequences are prone
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to spatial blurring in the slice-encoding/ z-direction and have lower GM-to-WM CBF
contrast ratio compared to 2D EPI readouts283.
Finally, physiological modulators of CBF such as hematocrit, caffeine, time of
day, exercise, posture, age, sex, wakefulness and vasoactive pharmacological agents
(indomethacin, acetazolamide) can confound hemodynamic measurements67. The
influence of these factors are minimized by imaging all subjects in the same examination
state (supine, eyes-open, caffeine- and pharmacological-free) or during post-processing
using covariate analysis methods.

1.8
Do local alterations in hemodynamics signify
impairment in neuronal activity?
A long standing notion in functional imaging of neuronal activity is the close
spatial correlation of CBF to glucose metabolism and oxygen consumption285, prompting
the use of CBF as surrogate markers of function. Changes in CBF are also spatially and
temporally correlated to neural activity286. Visual stimulation for instance results in an
increase in CBF to the visual cortex, while motor stimulation produces localized
hyperaemia in the motor cortex. Given the wide availability of MRI systems and
relatively lower cost of performing MRI scans compared to PET, the clinical relevance of
adopting ASL-CBF measurements as suitable makers of brain health is appealing.
Cerebral glucose metabolism (CMRglc) measured using

18

F-labeled fluorodeoxyglucose

(FDG) and PET is considered the gold standard measure of brain function. Good
agreement between regional CMRglc and regional CBF measured by PET and ASL
respectively have been reported in healthy adults during rest287, and visual stimulation286.
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In Alzheimer's disease patients, similar regional pattern of hypoperfusion and
hypometabolism were observed when PET-FDG was compared to ASL-CBF288.
However, the extent of CBF and CMRglc coupling is unclear and recent evidence
using improved ASL techniques outlined above, suggest that regional variations in
correlation of CBF and CMRglc may exist at rest287. It is equally unclear if age and
pathological disease disrupt the coupling of CBF with CMRglc. Goyal et al85 recently
demonstrated that changes in CMRglc and CBF are closely matched during normal
development, diverging over time during adulthood. In adults, changes in CBF correlated
more with CMRO2 than CMRglc85. A clear pattern emerging from recent correlation
studies, is that regions of the brain associated with higher order cognitive processing and
perception such as the default mode network including the medial prefrontal, lateral
temporal, posterior cingulate cortex and precueus, show the largest mismatch between
flow and glucose metabolism147,287,289. Whether the flow-glucose mismatch in these
regions are a normal variant of resting brain function is unknown. It is quite possible that
given the significance of these brain regions in fundamental functional organization of
the brain, these regions might retain a relatively high CBF-to-CMRglc ratio compared to
other brain regions at rest287,289. It is interesting that these brain regions also have higher
vulnerability to aging and vascular disease effects (see section on normal and
pathological brain aging).
A potential source of variance in correlating regional CBF and CMRglc might be
image registration errors. All previous comparison studies were carried out using separate
PET and MRI scanners, requiring the need to accurately align images obtained from the
two modalities, which were often acquired on different days. Since limitations in spatial
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resolution occur in both modalities, errors in image alignment can increase the mismatch
between CMRglc and CBF. Novel hybrid PET-MR imaging systems introduced in the
last 5 years can offer insights into regional association of blood flow to brain metabolism,
and affirm the use of ASL-CBF measures as suitable surrogate for PET-FDG in
measurements of brain function.

1.9

Thesis Outline

This thesis work represents a concerted effort at investigating cardiovascular
disease contributions to pathological brain aging within a cohort of coronary artery
disease patients, and the potential benefits of physical activity. The significance of ASL
perfusion imaging as surrogate marker of brain function was also investigated.

1.9.1

An investigation of changes in regional gray matter volume
in cardiovascular disease patients, pre and post
cardiovascular rehabilitation (Chapter 2).
Regional changes in GM volume associated with cardiovascular disease were

assessed in coronary artery disease patients compared to age-matched controls. Evidence
of improvements in brain structure with exercise was investigated after 6-month aerobic
exercise training. Regional GM volume was measured using voxel-based morphometry.
This work was published in NeuroImage Clinical, 2013; (3) 388-395 by: U. C. Anazodo,
J.K. Shoemaker, N. Suskin, and K. S. St. Lawrence.
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1.9.2

Impaired cerebrovascular function in coronary artery
disease patients, and recovery following cardiac
rehabilitation (Chapter 3).
Cardiovascular disease can impair the brain's hemodynamic function. To

investigate regional changes in cerebrovascular hemodynamics, independent of
underlying changes in brain structure. pCASL images were acquired at rest and during
inhalation of moderate concentrations of CO2 in the same cohort of coronary artery
disease patients and age-matched controls. Regional comparisons in CBF and CVR were
performed at baseline between patients and control, and within a subset of patients after 6
months of exercise training. Gray matter volume images from VBM were used as
confounding variables to separate changes in structure from function. This work is under
review in Journal of Cerebral Blood Flow and Metabolism [Manuscript ID: JCBFM0365-15], submitted by Udunna C Anazodo, J Kevin Shoemaker, Neville Suskin, Tracy
Ssali, Danny JJ Wang, and Keith S St. Lawrence.

1.9.3

Simultaneous whole-brain imaging of cerebral perfusion and
glucose metabolism on a hybrid PET-MRI scanner (Chapter
4)
In this chapter, regional association of resting CBF and CMRglc were performed

in healthy brains of older adults, using the novel integrated PET-MRI scanner. This
hybrid scanner allowed simultaneous imaging of ASL-CBF and PET-FDG, minimizing
potential misalignment errors. To improve the accuracy of the PET signals measured, a
novel method for correcting PET signal loss (attenuation) due to absorption in the body
or scatter by MR hardware is also presented. This chapter is based on the paper entitled
"Feasibility of simultaneous whole-brain imaging on an integrated PET-MRI system
51

using an enhanced 2-point Dixon attenuation correction method" published in Frontiers
in Neuroscience, 2015; (8): 434, by: Udunna C Anazodo, Jonathan D Thiessen, Tracy
Ssali, Jonathan Mandel, Matthias Günther, John Butler, William Pavlosky, Frank S Prato,
R Terry Thompson, and Keith S St. Lawrence.

1.9.4

Conclusion and Future Work (Chapter 5)
A summary of significant findings of the thesis are presented in this chapter.

Clinical relevance and areas for further exploration are described.

1.10
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2

Chapter 2
An investigation of changes in regional gray matter volume in
cardiovascular disease patients, pre and post cardiovascular
rehabilitation.

2.1

Introduction

According to the Institute of Medicine, the age standardized mortality rate from
cardiovascular disease has declined steadily over the past 50 years in industrialized
nations1. Much of the decline can be attributed to effective management of risk factors
associated with the disease. However, in the developed world, cardiovascular disease still
remains the most prevalent chronic disease in individuals over the age of 50, and the
debilitating effects of the disease are evident by the high rate of hospitalization amongst
this patient group2. Therefore, there is heightened urgency to understanding the impact of
cardiovascular disease on 'successful aging', particularly given that the number of adults
over the age of 60 is steadily increasing.
One growing concern is the potential link between cardiovascular disease risk
factors and neurological impairment in older adults. Hypertension, diabetes and
hyperlipidemia have been independently linked to abnormal changes in morphology and
function of the aging brain3. Older individuals with higher estimated risk of coronary
artery disease (CAD) tend to have decreased brain volume, cerebral blood flow, and
glucose metabolism in regions of the brain associated with cognitive function and, as
such, are at a greater risk of dementia3. Even in older adults with no clinical diagnosis of
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cardiovascular disease, decline in cardiac function is associated with deficits in cognitive
function4, brain atrophy5 and white matter hyperintensity6.
Despite the above studies involving cardiovascular risk factors, there have been
no similar studies on the impact of cardiovascular disease, more specifically CAD, on
normal age-related changes in regional brain morphology. Coronary artery disease is the
most common form of cardiovascular disease in adults over 50 years old with known
pathophysiology7 and effective management strategies8. Physical activity is one of the
most powerful and readily available interventions with proven efficacy in preventing
secondary CAD. Physical activity, specifically aerobic fitness has been shown to improve
coronary flow, lower the risk of myocardial reinfarction, lower mortality rates, and
improve overall cardiac function9. Consequently, increased levels of physical activity are
increasingly prescribed as part of the clinical management for CAD10. In older adults,
physical activity has also been associated with improved cognitive function11, decreased
risk for dementia12 and reversal of cortical decline13.
These observations highlight the need to investigate the association between CAD
and brain structure and whether interventions, such as physical activity, can reverse any
adverse disease-related effects. The objectives of this study were twofold: 1) to
investigate potential differences in regional gray matter volume in patients recently
diagnosed with CAD compared to controls, and 2) to determine if a standard cardiac
rehabilitation regimen would reverse CAD-related structural changes.
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2.2
2.2.1

Methods
Participants

This study was approved by the Western University Health Sciences Research
Ethics Board, and written informed consent was obtained from all subjects. CAD patients
were recruited from the London Health Sciences Centre for Cardiac Rehabilitation and
Secondary Prevention program following recent diagnosis of one of the following: acute
coronary syndrome (ST elevation or non-ST elevation myocardial infarct), angina,
percutaneous coronary intervention, or coronary artery bypass surgery. Patients were
excluded if they had congenital coronary abnormality, cardiomyopathy, severe
congestive heart failure, second or third-degree atrioventricular block, more than two
myocaridal infarcts, sick sinus syndrome, or major arrythmias. Patients with uncontrolled
hypertension or a history of diabetes for more than 5 years were also excluded. Agematched control subjects included in this study had no clinical diagnosis of
cardiovascular disease, were non-smokers, and did not have hypertension or diabetes.
Both patients and controls were free of any neurological condition or disease.

2.2.2

Clinical assessments of health
The relevant clinical markers of CAD measured in all subjects are described

below. A standard three-lead electrocardiogram was conducted after 20 minutes of supine
rest. Blood pressure was continuously measured during electrocardiogram using a
Finometer, which was calibrated against periodic sphygmomanometric measurements
(Dinamp, GE Healthcare, Finland). Blood-borne markers of vascular disease namely;
plasma lipids, cholesterol, high-sensitivity C-reactive protein (hs-CRP) and glucose, were
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collected under fasting conditions. A Doppler echocardiography (GE/Vingmed System
FiVe Doppler) was completed prior to cardio-respiratory exercise stress testing to assess
left ventricular ejection fraction, left ventricular mass and left ventricular contractility. A
test of global or overall cognitive function was performed with the Montreal Cognitive
Assessment, MoCA (http://www.mocatest.org/). Cardiorespiratory fitness was measured
by a graded exercise test in which subjects were tested to volitional exhaustion under
standard clincial observation (ACSM 1995)14. Breath-by-breath measurements of oxygen
consumption (VO2), heart rate and blood pressure were recorded throughout the test.
Maximal oxygen consumption (VO2max) is an established marker of cardiorespiratory
fitness and a clinically accepted surrogate maker for left ventricular function15. Each
subject's VO2max was estimated from the graded exercise test.

2.2.3

Clinical assessments of cardiac rehabilitation
The aerobic exercise component of the cardiac rehabiliation (CR) program was

performed according to current guidelines16 at an intensity of 40-70% of heart rate
reserve (i.e., the difference between the age-predicted maximum and resting heart
rates)17, or at a rate corresponding to an exertion score of 11-14 on the Borg scale18.
Aerobic exercise was performed a minimum of 3 days per week at a duration of 20-to-30
minutes per session.

2.2.4

MRI data acquisition
Whole-brain MRI images were acquired on two Siemens 3T MAGNETOM®

Verio systems (Siemens Medical Systems, Erlangen, Germany) equipped with 32-
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channel head array coils. Sagittal T1-weighted images were acquired on each subject for
gray matter volumetric analysis using a three-dimensional (3D) magnetization-prepared
rapid gradient-echo imaging sequence (isotropic voxel resolution=1.0mm3; repetition
time, echo time and inversion time = 2000, 2.98 and 900ms, respectively; acceleration
factor = 3; and flip angle=9 degrees).

2.2.5

Voxel-based morphometery analysis

2.2.5.1

Effects of disease

T1-weighted images were segmented into gray matter (GM), white matter (WM)
and

cerebrospinal

fluid

(CSF)

using

the

segmentation

option

in

SPM8

(http://www.fil.ion.ucl.ac.uk). The tissue segments were then affine-registered to their
respective Montreal Neurological Institute (MNI) tissue probability maps, averaged and
smoothed with a 12-mm filter using DARTEL to create a study-specific template19. The
individual GM images were spatially normalized to this template using a highdimensional DARTEL registration and then multiplied by the Jacobian determinant (i.e.,
modulation) to correct for nonlinear differences in individual brain size. Finally, the GM
images were smoothed with an 8-mm Gaussian filter. Local differences in GM volume
(GMV) between groups were investigated with a gender-by-group two-factor analysis of
variance, performed on the smoothed GMV images. An absolute threshold mask set at
0.1 was used to remove non-GM and extra-cranial effects. A significant positive effect of
disease was identified at voxel levels that differed between groups at p<0.05 after
correction for multiple comparisons using the false discovery rate (FDR)20.
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2.2.5.2

Effects of Rehabilitation:

Pre and post CR T1-weighted images of the CAD patients were analyzed with the
default options of the longitudinal module found in the VBM8 toolbox of SPM8. Briefly,
each subject's data were analyzed in a series of steps that included; 1) intra-subject
registration, 2) intra-subject bias correction, 3) segmentation, 4) non-linear DARTEL
registration to study-specific template, 5) modulation of GM segments, and 6) spatial
smoothing with an 8mm Gaussian filter. A repeated measures analysis of variance of the
change in GM volume over time was performed on the smoothed GM image with a
within-subject factor of time and between-subject factor of scanner. Gender-by-time
analysis of variance was also explored. A positive significant change was identified at
voxel levels that showed positive change in volume for p<0.05 after correction for
multiple comparisons using the more stringent family wise error (FWE). An absolute
threshold mask was also set at 0.1.
To investigate evidence of GMV recovery with CR, binary masks of regions of
interests

(ROIs)

were

created

using

the

MarsBaR

ROI

toolbox

(http://marsbar.sourceforge.net) from clusters of voxels that showed statistically
significant decline in GMV in the CAD group compared to controls (see table 2.2) with
minimum voxel clusters of 50 contiguous voxels. Small volume correction was
performed in SPM8 on contrast images from the repeated analysis of variance with the
ROIs to restrict multiple comparisons to a smaller number of voxels, which reduced type
II errors. Areas of GM recovery are reported as significant if clusters survive FWE
correction at p<0.05.
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2.2.6

Statistical analysis
Statistical analyses were conducted with SPSS 20.0 statistical software (IBM

Corp. Armonk, NY, and USA). Clincal assesments from the control group was compared
to baseline data from the CAD patient group using a one-way multivariate analysis of
variance to test for differences in cardiovascular health and cognitive function. Clinical
parameters entered into the multivariate analysis for cardiovascular health include all
variables listed in Table 2.1 except for age, gender, MoCA and VO2max. Gender
differences between groups was assessed by gender-by-group interaction and simple
main effects of gender. Significant interaction and main effects are reported at p <0.05.
Spearman rank correlation analysis was performed between baseline total gray
matter/ROI volumes and baseline MoCA scores, VO2max and other clinical measures
collected to investigate the association between overall cogniton, fitness level,
cardiovascular health, and brain atrophy. Total gray matter volume in mm3 for each
subject was obtained from the VBM8 segmentation output, while mean values of regional
gray matter volume were extracted from voxel clusters that showed significant difference
between groups for each subject using MarsBaR, as described earlier.
A paired t-test was conducted on the clinical variables collected on the CAD
patients pre and post CR to test for a difference between the means (p<0.05). To test for
association between fitness level and GMV post CR, a Spearman rank correlation
analysis was performed between VO2max and total gray matter/ROI volumes obtained
from post CR data, and between change in GMV and change in VO2max post CR.
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2.3
2.3.1

Results
Cardiovascular disease effects

A total of 41 CAD patients and 21 controls participated in the study; their
characteristics are provided in Table 2.1. Data from three controls and two CAD patients
data were removed because of neurological incidental findings in the MRI data. Data
from 36 patients and all controls were collected on one scanner, while data from the last 5
patients were acquired on a separate, but identical, scanner during the upgrade of the first
one. All control subjects and 18 CAD patients completed the graded exercise testing with
cardiorespiratory measures to maximum volitional exhaustion to establish maximal
oxygen uptake (VO2max).
The CAD group comprised of patients with clinical diagnosis at referral of angina
(12.1%), myocardial infract (12.1%) and coronary artery disease (69.7%). All patients
were on a combination of drug therapy and 36.8% had percutaneous coronary
intervention while 7.9% received coronary artery bypass grafting. Drug therapy included
cholesterol lowering/statins (87.2%), beta-blockers (76.9%), ACE-inhibitors/Angiotensin
II receptor blockers (56.4%) and anti-platelets including aspirin (84.6%). There were no
significant interactions between gender and group for any of the clinical measures,
including markers of fitness. No significant differences between patients and controls
were found for measures of blood pressure, cardiac output, left ventricular ejection
fraction, resting heart rate and blood glucose. However, compared to control, CAD
patients had lower MOCA scores (F =4.3 (1,53), p< 0.05), lower VO2max (F = 17.04
(1,53), p< 0.001), lower total cholesterol levels (F = 16.22 (1,56), p< 0.001), elevated
body mass index, BMI (F = 17.86 (1,56), p<0.001), and increased hs-CRP levels (F =
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7.40 (1,55), p< 0.01). There was also significant difference in level of education (p
=0.031), as defined by the number of years of formal education, between patients (15.5 ±
2.7 years) and controls (18.3 ± 4.3 years).

Table 2.1: Study participant characteristics. The mean and standard deviation are
presented for clinical variables measured at baseline in CAD patients and controls.
Variable

Controls (n=21)

Pre-CR CAD patients (n=39)

Age

59 ± 8

59 ± 7

Gender (men/women)

11/10

28/11

BMI

24.8 ± 3.3

29.8 ± 4.7a

Fasting blood glucose (mmol/L)

4.75 ± 0.88

5.23 ± 1.32

Total cholesterol (mmol/L)

4.17 ± 0.94

3.16 ± 0.79a

hs-CRP (mg/l)

0.95 ± 0.89

2.25 ± 3.10a

121 ± 16

127 ± 22

69 ± 8

71 ± 12

Left ventricular ejection fraction (%)

68 ± 9

64 ± 8

Resting heart rate (beats per minute)

59 ± 10

59 ± 7

MoCA

28.16 ± 1.7

26.86 ± 2.1a

VO2max (mL/min/kg)

37±2

26±2a

Rest supine systolic blood pressure
(mmHg)
Rest supine diastolic blood pressure
(mmHg)

a = Statistical difference between groups at p<0.05
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VBM results of regional GMV differences between patients and controls
are shown in Figure 2.1, and the corresponding MNI coordinates and Talairach
anatomical labels are listed in Table 2.2. In general, the CAD patient group exhibited
significantly lower GMV in the frontal lobe, parietal lobe, temporal lobe, and cerebellum.
There was a significant difference in total GMV (F = 5.5 (1, 53), p< 0.05) between
groups but no statistical difference in total intracranial volume. There were moderate
positive associations between VO2max and total GMV (ρ = 0.420 (38), p< 0.001), and
GMV in the left posterior cerebellum (ρ = 0.616 (38), p<0.001) and right post central
gyrus (ρ =0.403 (38), p<0.01). There was no significant gender-by-group interaction, nor
was there any correlation between total/regional GMV and MoCA scores or any other
clinical parameter measured. Repeating the VBM analysis after removing the data from
the 5 patients acquired on the second system had no effect on these results, except to
reduce the effect size of the observed regional changes by 5 ± 13%.
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Figure 2.1: Differences in GMV between CAD patients and age-matched controls
measured at baseline.

t-statistics displayed on a rendered model of a single subject brain. The red blobs on coronal, sagittal
and transverse planes indicate areas of decreased GMV in the CAD patient group.
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Table 2.2: Local maxima of clusters of significant change in GM volume in the preCR CAD patient group compared to controls.

L superior frontal gyrus
L superior frontal
L medial frontal
R superior frontal gyrus
L frontal lobe (rectal gyrus)
R superior frontal

10
10
11
10
11
10

MNI
Coordinate
x
y z
-22 57 -10
-18 55 -23
-27 45
-6
18 58 -10
0
48 -23
14 54 -15

1515

L posterior cerebellum

NA

-40

-68

-12

4.90

4

510

R posterior cerebellum

NA

3

-73

-3

4.73

5

799

R medial frontal gyrus
L medial frontal gyrus

9
8

9
-6

47
45

29
29

4.64
3.74

6

674

R inferior frontal gyrus

47

42

15

-3

4.52

7

977

40
4

-56
-51

-20
-13

19
42

4.42
3.74

8

202

44
4

-53
52

4
-5

16
15

4.41
3.50

9

774

R orbitofrontal

11

22

38

-22

4.33

10

1601

L Inferior frontal gyrus
L Insula

47

-42
-33

28
17

-1
0

4.31
4.01

11

134

L inferior parietal gyrus

40

-42

-36

41

4.13

12

518

R inferior parietal lobe

40

51

-33

40

4.07

13

83

L middle temporal gyrus

37

-51

-55

0

4.02

14

127

R superior parietal gyrus

7

24

-58

61

3.96

15

141

L temporal lobe (Fusiform)

37

-50

-42

-10

3.71

16

270

L superior temporal gyrus

38

-33

5

-17

3.63

17

50

R superior temporal gyrus

38

44

3

-19

3.50

18

69

R inferior temporal gyrus

20

39

-22

-31

3.45

Cluster
Number

Volume (mm)

1

2688

2

1831

3

Anatomical label

L parietal lobe (post central
gyrus)
L Frontal (precentral gyrus)
L inferior frontal gyrus
L parietal (precentral)

Brodmann
Area

tvalue
5.03
3.00
4.66
4.96
4.76
3.81

R anterior cingulate gyrus
32
6
25 30
3.38
(dorsolateral)
Coordinates are given in anatomical MNI space and maxima are shown at least 8.0 mm apart. The
center of mass of each ROI is shown in bold. L = left; R = right.
19

74
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2.3.2

Effects of cardiac rehabilitation
Twenty-four CAD patients (18 men and 6 women) completed the 6-month CR

program and post-CR testing. The MRI data, pre and post rehabilitation, from the last
five patients were acquired on the second scanner. Fifteen patients completed graded
exercise testing to maximum volitional exhaustion on entry and exit from the CR
program. No statistically significant differences were found in any of the clinical
parameters between the pre and post CR tests. In addition, there was no change in MoCA
scores (p =0.3) after 6 months of CR. There was a trend (5%) towards increased VO2max
(p=0.06) in the 15 patients tested after 6 months of CR.
Regions of positive change in GMV from VBM analysis of CAD patients, pre and
post CR, are listed in Table 2.3 and displayed on Figure 2.2. The main increases in GMV
after 6 months of CR were observed bilaterally in the frontal lobe, middle temporal gyrus
and supplementary motor area (Table 2.3). Small clusters of increase in GMV were
observed in some of the regions affected by CAD (see Table 2.4), signifying a recovery
of volume following CR. There was no change in total GMV or total intracranial volume
after CR. No significant correlation was found between VO2max post CR and regional
GMV and between change in VO2max and regional increase in GMV. There was no
significant scanner-by-time interaction or gender-by-time interaction (p<0.05, FWE) and
no difference in GMV or clinical measures between patients that successfully completed
exercise testing and patients that were unable to.
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Figure 2.2: GMV changes over time in CAD patient pre and post CR.

t-static displayed on a rendered model of a single subject brain. Red blobs on coronal, sagittal and
transverse planes indicate areas of increased GMV in the CAD group after 6 months of CR.
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Table 2.3: Local maxima of clusters of significant change in GM volume in the CAD
post CR (Post >Pre).
Cluster
Number

Volume
(mm)

Anatomical label

Brodmann

MNI Coordinate
t-value

Area

x

y

z

1

1095

Right frontal(paracentral) lobe

6

8

-33

66

13.67

2

304

Left middle temporal gyrus

21

-62

-60

9

11.63

3

504

Left frontal (paracentral) lobe

6

-8

-28

66

10.70

Right anterior cerebellum

NA

3

-55

4

10.37

Left posterior cerebellum

NA

0

-73

-8

8.92

Left cerebellum

NA

-8

-81

-15

8.44

4

782

5

191

Right superior frontal gyrus

10

22

63

-8

10.26

6

122

Left inferior temporal gyrus

20

-32

0

-47

8.88

7

1175

Right superior temporal

38

22

8

-45

8.88

Right superior temporal

22

64

-42

10

8.12

Right middle temporal gyrus

22

66

-34

4

7.84

8

427

9

246

Right frontal (precentral) gyrus

6

56

0

31

7.79

10

28

Left superior temporal gyrus

22

-56

11

-2

7.33

11

54

Left medial frontal gyrus

10

-3

66

6

7.27

13

93

Right medial frontal gyrus

6

4

-19

54

7.13

Coordinates are given in anatomical MNI space, and maxima shown are at least 8.0 mm apart. The
center of mass of each ROI is shown in bold. Corrected for multiple comparisons (FWE, p < 0.05).

96

Table 2.4: Cluster of GMV recovery after 6 months of CR (N=24). Small volume
correction (p<0.05, FWE).
Cluster
Number

Volume
(mm)

Anatomical label

Brodmann

MNI Coordinate

Area

x

y

z

t-value

1

128

Right superior frontal gyrus

11

22

61

-10

10.26

2

23

Right middle temporal gyrus

22

67

-37

13

7.20

3

99

NA

0

-72

-3

8.92

2.4

Left posterior cerebellum (declive
of vermis)

Discussion

The key findings of the current study were lower GMV in the prefrontal cortex,
parietal and temporal lobes of CAD patients compared to age-matched controls (Figure
2.1 and Table 2.2) and increased GMV in the superior frontal gyrus, medial frontal gryus
and superior temporal gryus after 6 months of cardiovascular rehabilitation (Figure 2.2
and Table 2.3). This study is the first to show evidence of regional cortical brain atrophy
associated with cardiovascular disease and also the ability of cardiovascular rehabilitation
to reverse disease-related cortical atrophy.

2.4.1

Cardiovascular disease effects
Our CAD group were patients diagnosed with either angina or myocardial

infarction who were all receiving some form of treatment prior to the start of the study.
Most patients were on a combination of drug therapy to lower lipid levels, maintain blood
pressure, and to prevent reinfarction. The therapeutic impact of these treatments might
97

have contributed to the lack of any statistical differences in fasting blood glucose, resting
supine blood pressure, cardiac output or heart rate between patients and controls. The
CAD patients had lower lipid levels compared to controls, which can be attributed to the
efficacy of statins in reducing serum levels of cholesterol21. However, mean hs-CRP, a
marker of inflammation associated with increased risk of myocardial infarct or
reinfarction, was higher for CAD patients than controls.

2.4.2

CAD-related effects: Brain atrophy
The findings of decreased GMV in the frontal, temporal and parietal lobes of

CAD patients are similar to the patterns of brain atrophy previously observed in patients
with either hypertension or diabetes, in which marked declines in GMV were found in the
prefrontal cortex, superior temporal and middle temporal lobes, thalamus, and
hippocampus3. The regions common to all of these studies are associated with varying
cognitive functions – executive function, attention, and memory, visuospatial and
psychomotor speed – and are believed to be susceptible to vascular disease22. A study of
400 men over the age of 40 found that cardiovascular disease was associated with poor
performance in memory tests and a trend towards lower scores in mini-mental state
examination23. Similarly, Okonkwo et al.24 reported an accelerated decline in the
aforementioned cognitive domains in a large group of cardiovascular disease patients
over a three year period that was not attributed to aging. In addition, numerous studies
have

linked

markers

of

cardiovascular

disease

including

impaired

vascular

hemodynamics (pulse wave variability, arterial stiffness, and ventricular function) to
alterations in cognitive function25,26. In general, the observation of decreased GMV in the
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frontal, temporal and parietal lobes indicates that CAD accelerates age-related neocortical
degeneration, possibility leading to declining cognitive function.
Our findings of bilateral atrophy in the posterior cerebellum and in the inferior
parietal lobule of the brain in the CAD group is novel given that these regions are usually
preserved with age and atrophy has only been reported in a few dementia studies27,28.
These studies linked poor performance on short-term memory and visuospatial tasks to
GMV decline in either the cerebellum27 or the inferior parietal lobule28, highlighting the
known importance of both regions in neurocognitive integration. Taken together, these
observations suggest that in older adults, cardiovascular disease can precipitate changes
in normally stable regions of the brain.
A significant difference in mean baseline MoCA scores between the CAD group
and controls was found in the current study (Table 2.1). 24% of CAD patients had a score
of 25 or less compared to 5% of controls. A MoCA score of less than 26 is typically
considered to reflect mild cognitive impairment (MCI). However, there was no
correlation between MoCA scores and regional brain atrophy. Considering the MoCA is
a brief assessment tool of MCI29, it may not be ideal for probing subtle cognitive decline
in middle-aged adults since evidence of cognitive decline typically occurs after the age of
6030. The apparent difference in MoCA scores between groups could possibly be a mere
reflection of the difference in levels of education observed between groups. Education
was associated with performance on MoCA (r=0.518, p<0.01), but not total or regional
GMV. Similarly, Christensen et al31 found no link between level of education and global
or regional brain atrophy in adults with no history of cognitive impairments. The use of
tests more specific to the cognitive functions associated with the observed areas of brain
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atrophy might reveal greater impairment. Nonetheless, the current data support the
overall concern that CAD accelerates cortical atrophy with detrimental outcomes to
cognitive ability.
The direct mechanism(s) that drive the greater brain atrophy associated with
cardiovascular disease are unclear. One possible mechanism could involve cerebral
hypoperfusion. Animal studies have shown that cerebral hypoperfusion from ischemic
vessels can initiate pathophysiological changes in the brain structure and function of
aging rats, resulting in decreased synaptic activity and impaired memory and visuospatial
skills32. Human studies of diabetic and hypertensive patients have reported regional
cerebral hypoperfusion in similar regions of the brain where atrophy has been
reported33,34. Investigating cerebral blood flow or cerebrovascular dynamics with
morphometric imaging would help elucidate potential neurovascular changes in CAD
patients.
A common cause underlying both CAD and brain atrophy could be physical
inactivity. Physical inactivity is an important modifiable risk factor for heart disease
given that inactive individuals are twice as likely to suffer a coronary event in their
lifetime compared to physically active individuals35. In this study, the CAD patients were
40% less fit than controls and the less fit individuals were more likely to have lower
global and regional GMV. In general, physical inactivity is associated with regional brain
atrophy36 and cognitive decline37 in healthy older adults.
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2.4.3

Effect of rehabilitation: neuroplasticity
The propensity for age and CAD to adversely affect the function and morphology

of certain regions of the brain, namely the prefrontal, superior parietal, inferior temporal
and middle temporal, suggests that these regions are highly malleable and perhaps more
adaptive to change. Recovery of volume within these brain regions with exercise in both
healthy aging subjects and dementia patients signifies that these regions are highly
plastic11,38,39. These observations are in good agreement with our finding of increased
GMV in the prefrontal, left middle temporal, left inferior temporal lobes in addition to the
cerebellum, supplementary motor areas and right superior temporal gyrus of CAD
patients after 6 months of CR.
The significance of aerobic fitness in improving cardiovascular and cerebral
functions is well established and discussed in great detail in reviews by Erickson et al39
and Lavie et al40. Briefly, with CAD, aerobic fitness is associated with a significant
decrease in relative risk of mortality, improved ventricular function, and improved
vascular dynamics41. In older adults and dementia patients, exercise training was
associated with increases in regional brain volume, improved cognitive function, and
increased neuronal activity40. Increases in regional GMV13,42 and cognitive function43
have been reported after 6 months of moderate level of exercise training (40-70% of heart
rate reserve). The prescribed 6 months of aerobic exercise, as part of the CR program,
was sufficient to cause detectable changes in brain structures of CAD patients including
changes in non-motor areas, despite the observed modest impact on aerobic fitness.
Findings of recovery of GMV in areas of the superior frontal lobe, superior
temporal lobe and posterior cerebellum (Table 2.4) after a short period of exercise are
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promising and indicate a unique positive outcome of CR. It could be postulated that
recovery of brain volume in these regions could potentially be maintained over longer
periods. Erickson et al.43 found retention of regional brain volume in older adults that
performed low intensity exercise nine years after cessation of the activity.

2.4.4

Study consideration
The impact of cardiac artery bypass grafting surgery (CABG) on neuroanatomy

and cognitive function cannot be ignored. CABG is known to exert transient decrease in
brain volume and cognitive function44. The interaction between cardiovascular disease
and CABG on regional GMV was not explored given that only 8% of CAD patients in
this study underwent CABG and this occurred a few months prior to the start of the
study.
It is possible that the GMV changes observed post CR in CAD patients might not
reflect the full potential neurorehabiltatory benefits of CR giving the moderate
improvement in GMV post exercise training. Considerable changes could be achieved
with either high-intensity aerobic exercises or activities such as basket ball, hockey or
squash that incorporate motor skills along with cognitive and perceptual skills (areas
which showed significant GMV decline with CAD). The lack of association between
VO2max and GMV could be a result of the large number of patients who were unable to
complete the graded exercise test for various reasons including the inability to reach
maximal volitional exhaustion, which is common among CAD patients. Submaximal
graded exercise tests or a 6 minute walk test could be used to evaluate cardiorespiratory
capacity in CAD patients who cannot achieve maximal myocardial oxygen uptake.
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However, submaximal VO2 tests often lack diagnostic accuracy, particularly tests that
exclude heart rate measures with electrocardiography.
The innate methodological limitations of VBM are also drawbacks to the
interpretation of our findings. The registration, segmentation and normalization steps in
VBM can introduce bias and distortion errors particularly in the border of small
subcortical GM structures where some proximal voxels can be misclassified45,46. This
error is exaggerated in older brains prone to enlarged ventricles. We minimized these
distortion errors with the use of a study-specific template and DARTEL registration
method19,46. However, this inherent segmentation and registration bias can pose a
limitation to the investigation of CAD-related regional brain volume changes in
vulnerable subcortical regions such as the hippocampus where decline in volume have
been previous reported in CAD47. For longitudinal studies, available intra-subject bias
correction methods attempt to minimize the influence of baseline differences on images
from subsequent time points. However, issues of registration asymmetry can be largely
improved with symmetric diffeomorphoic approaches proposed for future versions of
SPM, particularly for non-quantitative T1-imaging data48.
A potential limitation with this study was the use of two scanners in data
acquisition. However, performing the analysis of the effects of CAD without the five
patients imaged on the second scanner revealed no difference in the pattern of regional
GMV differences reported in Table 2.2 and shown in Figure 2.1. Furthermore no
significant effect was found by including scanner as a between-subject factor in the
analysis of the rehabilitation data.
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2.5

Conclusion

This study demonstrates that in stable CAD patients, cardiovascular disease is
associated with brain atrophy in several brain regions, including those related to cognitive
ability. This disease-related effect appears to be reversible as this study demonstrated that
a modest aerobic program reversed some of the structural abnormalities.

2.6
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3

Chapter 3

Impaired Cerebrovascular Function in Coronary Artery Disease
Patients, and Recovery Following Cardiac Rehabilitation.

3.1

Introduction:

Cardiovascular disease increases the rate of age-related cortical atrophy1, the risk
of dementia2, and the risk of stroke. These relationships likely are due to progression of
vascular disease into the cerebral circulation. Cerebrovascular disease and alterations to
the structure and function of the brain are increasingly associated with cardiovascular
disease risk factors such as hypertension, atherosclerosis and diabetes3. This comorbidity
of cardiovascular disease and neurological impairments in older adults is a growing area
of concern, since aberrant brain changes related to vascular disease appear to affect
regions involved in cognitive function2.
A number of studies have demonstrated that vascular disease processes accelerate
brain decay and alter the natural age-related decline in cerebrovascular hemodynamics4.
In asymptomatic older adults, decline in cardiac output is associated with global brain
atrophy5, regional cerebral hypoperfusion6 and impairments in cognitive abilities7.
Recently, we observed significant reductions in regional brain volume in the brains of
coronary artery disease patients1 that are consistent with observations of cerebral atrophy,
hypoperfusion, and white matter disease in brains of older adults with increased risk for
vascular disease3. Although these observations suggest a possible link between
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cardiovascular disease and neurological dysfunction, the interaction of age, vascular
disease and cortical degeneration is complex and not well understood4,6. In addition, the
effect of cardiovascular disease on cerebrovascular hemodynamics and function has not
been fully characterized. Vascular diseases may accelerate cerebrovascular aging and in
doing so, significantly alter normal cerebral blood flow distribution, inducing brain
atrophy and cognitive decline6. However, no study to date has described regional
cerebrovascular hemodynamics in individuals with ischemic vascular disease.
Building

on

our

previous

work,

this

study assessed

cerebrovascular

hemodynamics and relationships between hemodynamic changes and brain atrophy in the
same cohort of coronary artery disease (CAD) patients and age matched controls.
Furthermore the therapeutic effects of cardiac rehabilitation on cerebral blood flow
(CBF) in CAD patients were assessed in a subsample. We explored regional changes in
CBF and cerebrovascular reactivity to CO2 (CVR) in cognitive areas of the brains of
CAD patients, since increased vascular resistance, common in CAD can diminish CVR8.
Measurements of CBF and CVR were performed using arterial spin labelling (ASL).

3.2
3.2.1

Materials and Methods:
Participants

Participants were part of a larger prospective study examining the effects of
cardiovascular disease on brain health. The CAD patients were recruited from the
London Health Sciences Center for Cardiac Rehabilitation and Secondary Prevention
program, and controls matched in age, were recruited from the local community. The
present sample are subjects from a previous study1 and consists of 34 CAD patients (58 ±
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7 years, 10 females) and 21 healthy controls (59 ± 8 years, 10 females) whom had MRI
scans that included ASL acquisitions. Of the 34 patients, 17 (59 ± 6 years, 5 females)
completed a 6-month CR program and participated in post-CR testing. CAD was defined
by a history of one of the following: acute coronary syndrome (ST elevation or non-ST
elevation myocardial infarct), angina, percutaneous coronary intervention, or coronary
artery bypass surgery. Exclusion criteria included patients with congenital coronary
abnormality, cardiomyopathy, severe congestive heart failure, second or third-degree
atrioventricular block, more than two myocaridal infarcts, sick sinus syndrome, major
arrythmias, uncontrolled hypertension or a history of diabetes for more than 5 years.
Controls were excluded if they had clinical diagnosis of cardiovascular disease,
hypertension and diabetes. All participants were free of neurological diseases,
pharmaceutical or nutraceutical psychostimulants, nootropics and non-smokers. This
study was approved by the Western University Health Sciences Research Ethics Board
and written informed consent was obtained from all participants.

3.2.2

Experimental design
Experimental data were collected over three testing sessions: 1) a laboratory

session for assessment of clinical markers of vascular health, 2) graded exercise testing
and 3) brain MRI. Subjects refrained from caffeine, alcohol and physical activity at least
12 h before participating in each session. To capture global cognitive function, the
Montreal Cognitive Assessment, (MoCA, http://www.mocatest.org) was administered
during the laboratory testing. MoCA scores were corrected for level of education defined by the total number of years of formal education, as described on
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http://www.mocatest.org. The entire experimental protocol was repeated in the 17 CAD
patients who performed 6 months of cardiac rehabilitation, which consisted of moderateintensity aerobic and strength fitness training. The aerobic training protocol was
performed as previously described1 and as prescribed by the London Health Sciences
Center Cardiac Rehabilitation and Secondary Prevention Program.
Cerebrovascular reactivity measurements were achieved by manipulations of
arterial concentrations of CO2. Subjects breathed room air for 5 min, followed by 5 min
inhalation of 6% CO2 mixed with 21% O2 and balanced nitrogen, while end-tidal partial
pressure of CO2 (PETCO2) was recorded continuously (Invivo 3150m, Invivo Corp.,
Orlando, Florida). Air and mixed CO2 were delivered via a non-rebreathing facemask
(Hans Rudolph Inc., Kansas City, Missouri) attached to a large non-diffusible gas
reservoir bag. The breathing rate was paced at 15 breaths/minute guided by a metronome
to minimize hyperventilation and maintain steady-state sampling of PETCO2. The
hypercapnia challenge was performed first in the laboratory in supine position to
acclimatize participants prior to repeating the challenge during brain imaging.
Participants unable to perform hypercapnia testing or who had a change in P ETCO2
(ΔPETCO2) of 5mmHg or less in the laboratory examinations did not perform the
challenge during the MRI session. Instead only resting CBF images were acquired.

3.2.3

Clinical measurements
To assess levels of plasma lipids, cholesterol, blood glucose, glycated hemoglobin

(HbA1c) and high-sensitivity C-reactive protein (hs-CRP), blood samples were collected
under fasting conditions and analyzed using standard assays and glucometer. Three-lead
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electrocardiogram and finger blood pressure monitoring (Finometer; Finapres Medical
Systems, Amsterdam, the Netherlands; calibrated to sphymomanometric values) were
performed concurrently over a 20 min period. Mean values for heart rate, systolic blood
pressure, diastolic blood pressure and mean arterial pressure were reported from
measures averaged over 5 min. Vascular hemodynamic measurements were performed on
the right common carotid artery using Doppler ultrasound imaging (Vivid 7, GE
Healthcare). Carotid vessel diameter, wall thickness and intima media thickness were
measured from 2-dimensional (2D) B-mode images acquired in the long-axis plane by a
single observer blinded to subject identity or group assignment. Arterial compliance and
distensibility were calculated from measures of vessel diameter and pressure at end
systole and end diastole9. A 2D transthoracic Doppler echocardiogram (Vingmed System
FiVe, GE Healthcare, Chalfont St Giles, UK) was performed to assess left ventricular
ejection fraction (EF) - a clinical index of cardiac function. Graded exercise testing was
performed to volitional exhaustion to measure cardiorespiratory fitness level or capacity
(maximal oxygen consumption, VO2 max), in accordance with the American College of
Sports Medicine guidelines for exercise testing.

3.2.4

MRI data acquisition
All MRI brain imaging was performed on a Siemens 3T Verio system (Siemens

Medical Systems, Erlangen, Germany) using a 32-channel head coil. The head was
immobilized with foam padding to minimize motion artefacts. Sagittal T1-weighted
images were acquired using a three-dimensional magnetization-prepared rapid gradientecho (MPRAGE) sequence (repetition time (TR), echo time (TE) and inversion time (TI)
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= 2000, 2.98 and 900 ms, flip angle = 9°, field of view (FOV) = 256 x 256 mm2, 176
slices, isotropic voxel size = 1.0 mm3, acceleration factor = 3) to measure cortical
thickness. ASL images were acquired during hypercapnia testing using a transverse 2D
gradient-echo echo planar imaging (EPI) sequence (TR/TE = 3500/12 ms, FOV = 240 x
240 mm2, 12 contiguous slices, 6 mm thickness, voxel size = 3.8 x 3.8 x 6 mm3,
bandwidth = 2298 Hz/Px, acceleration factor of 2) and a pseudo-continuous label
method10 applied 9 cm below the center of the imaging volume for a duration of 1.5 s.
One-hundred and ten label and control pairs were acquired after a 1.0 s post-label delay.
A non-selective inversion pulse was applied for background suppression during the postlabel delay. To improve signal-to-noise (SNR) and sensitivity of ASL for CVR
measurements, ASL imaging and hypercapnia testing were repeated after a 3 min
recovery period. Additional imaging for CBF quantification included; a) proton density
calibration scan (M0) acquired with the ASL sequence using a TR of 7 s and no label or
background suppression pulses, and b) axial single-shot inversion-recovery prepared
balanced steady-state free precession imaging (IR-TrueFISP) acquired with 10 variable
TI (175 to 8000 ms) on a single slice at the mid-sagittial section of the brain (TE = 1.21
ms, 1.7 x 1.7 x 4 mm, acceleration factor of 2). These images were used to measure the
longitudinal relaxation time of blood (T1b) in the sagittal sinus11.

3.2.5

Perfusion-weighted analysis
Preprocessing and analysis of perfusion data were performed with SPM8

(http://www.fil.ion.ucl.ac.uk) and scripts written in MATLAB (2012a, The MathWorks,
Natick, MA). All ASL and M0 scans were aligned to the first time point of the first scan
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to correct for head motion within sessions (two trials) and between sessions (pre and
post-CR). Intra-subject alignment was performed on MPRAGE images using the VBM8
longitudinal toolbox (http://dbm.neuro.uni-jena.de/vbm) in SPM8 to minimize intrasubject registration errors. Using a rigid-body transformation, respective MPRAGE
image volumes were aligned to corresponding ASL scans (i.e. baseline MPRAGE to
baseline ASL and post-CR MPRAGE to post-CR ASL), and segmented into gray matter
(GM), white matter (WM) and cerebrospinal fluid (CSF) probability images using the
new segment tool in SPM8. The GM segments were transformed into binary masks
thresholded for voxels with 80% or more GM content and applied to the ASL time series.
This was done to minimize ASL signal contributions from WM and CSF. Forty label and
control images were extracted from each 5 min block at steady-state, surround subtracted
and time-averaged over the two trials to generate perfusion-weighted (ΔM) images. CBF
was calculated using a standard single-compartment flow model10.
6000 ∙ 𝜆 ∙ 𝛥𝑀 ∙ 𝑒

𝐶𝐵𝐹(𝑚𝑙/100𝑔/𝑚𝑖𝑛) =

𝜔
𝑇1𝑏

2𝛼 ∙ 𝑀0 ∙ 𝑇1𝑏 ∙ 1 − 𝑒-

−

𝜏+𝜔
𝑇1𝑏

where λ = blood/tissue water partition coefficient, 0.9 g/mL; α = labelling efficiency
assumed to be 85%11 multiplied by 94% for background suppression; ω = post-labelling
delay of 1.0 s incremental per slice; τ = label duration of 1.5 s and T1b = individual blood
T1 value. The final individual normocapnia and hypercapnia CBF images were smoothed
using a Gaussian filter with a FWHM of 6 mm and transformed to standard stereotactic
space (MNI) using transformation parameters from segmentation of MPRAGE images.
CVR was calculated pixel-by-pixel as the increase in CBF per mm Hg increase in
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PETCO2. All further reference to CBF refers to CBF measured at room air, unless
otherwise stated.
To assess the sensitivity of the ASL sequence used in this study, the temporal
signal-to-noise ratio (tSNR) of the perfusion-weighted time series was calculated for each
subject. Temporal SNR was defined as the mean GM pixel signal relative to the mean
GM pixel standard deviation. The reproducibility of repeated ASL measurements was
determined from a subset of patients and controls (N=19) for baseline CBF and CVR
using within-sessions coefficient of variation and intraclass correlation coefficient (ICC).
ICC was calculated using SPSS and two-way random model with measures of
consistency, where a value close to 1 represents a high reliability. For completeness, the
test-retest reliability at baseline was also compared voxel-by-voxel using repeated
measures analysis of variance. This was done to ensure that averaging the perfusionweighted signal from the 2 trials did not bias group comparisons.

3.2.6

Assessment of structure-independent CBF effects
Our goal was to relate cerebral hemodynamic changes to underlying structural

changes in brain volume1 on a voxel-by-voxel basis to see if hemodynamic abnormalities
(i.e. hypoperfusion or reduced CVR) and brain atrophy were mutually dependent. Thus,
to delineate perfusion changes from underlying structural changes, a multimodal voxelby-voxel multivariate analysis was performed as a two-step process as outlined in figure
3.1. First, an exploratory analysis was performed on the CBF images across all voxels
with greater than or equal to 80% gray matter, to identify regions with significantly
different gray matter CBF between CAD patients and controls. This was achieved using
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two-tailed Student's t-test performed within SPM8. Next, these clusters were passed to
the biological parametric mapping (BPM)12 tool, where a voxel-by-voxel analysis of
covariance (ANCOVA) was performed on CBF images with differences in regional gray
matter volume (GMV) removed. The results reflected differences in regional gray matter
perfusion independent of gray matter volume changes.
For the BPM analysis, individual GMV images were generated from MPRAGE
volumes using voxel-based morphometry (VBM, http://dbm.neuro.uni-jena.de/vbm/) in
SPM8 as described in a prior study1. The GM segments were spatially normalized to a
template averaged from all subjects, corrected for differences in brain size and smoothed
with an 8-mm Gaussian filter. To describe changes in GMV within the clusters of
interest, a voxel-by-voxel between-group comparison was performed on the GMV
images and restricted to the clusters of interest using SPM8. An absolute threshold mask
set at 0.1 was used to remove non-GM voxels. For all statistical analysis, type I errors
from multiple comparison was minimized using False Discovery Rate (FDR) at p <0.05
and cluster size greater than 10 voxels.
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Figure 3.1: Illustration of the pipeline for multimodal voxel-wise ANCOVA
performed to determine the singular effect of CAD on regional CBF.

Step 1 involved SPM voxel-wise between-group comparisons of CBF images across the brain.
Significant clusters from this step were converted to binary masks and used in Step 2 to improve
voxel-wise multimodal analysis and limit type II errors. In step 2, between-group differences in CBF
were examined voxel-wise using BPM with GMV images from VBM analysis serving as covariates.
Corrections for multiple comparisons using FDR (p<0.05) was performed at each step. Clusters that
remained signified regions where CBF changes drive the observed differences as in figure 3.2B and as
listed in table 3.2. Illustration was overlaid on glass brains from SPM8
(http://www.fil.ion.ucl.ac.uk/spm/).

3.2.7

Statistical analysis
Statistical analyses were conducted with SPSS 20.0 statistical software (IBM

Corp. Armonk, NY, and USA). Baseline clincal assesments and regonal CVR measures
from CAD patients were compared to data from the control group using two-tailed
Student's t-test since age and gender were matched. Since, lower CVR was expected in
the CAD8 group compared to controls, a one-tailed t-test was performed on regional
mean CVR values extracted from each of the clusters from results of ANCOVA BPM
analysis. Voxel-by-voxel comparisons were not performed on CVR images because of
power constraints.
To test for effects of aerobic fitness, a paired t-test was performed on clinical data
and regional CBF measures acquired on a subgroup of CAD patients before and 6 months
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after cardiac rehabilitation. Regional CBF values were extracted from each of the clusters
from the baseline ANCOVA BPM analysis. To demonstrate recovery of CBF with
cardiac rehabilitation within regions, percent relative differences were computed for
CAD patients at baseline and after CR. Baseline differences were relative to each
regional mean CBF across all control subjects, while post-CR differences were relative to
pre-CR regional CBF values. For completeness, relative differences were also computed
for regional GMV. CVR analysis were not performed post CR due to a lack of statistical
power.

3.3
3.3.1

Results
Study demographics

Perfusion data from one control subject and one CAD patient at baseline were
excluded because of motion artefacts. Thirteen control subjects and 22 CAD patients
participated in CVR measurements. The CVR data of one patient were excluded due to
accelerated breathing (>25 breathes per minute) during hypercapnia, which can confound
CVR results. The CAD group consisted of patients with clinical diagnosis at referral of
angina (11.7%), myocardial infract (17.6%) and coronary artery disease (67.6%). All
patients were on a combination of drug therapy to lower lipid levels (statins = 83.3%),
maintain blood pressure (beta-blockers = 72.2%; ACE-inhibitors/angiotensin II receptor
blockers = 50%) and prevent reinfarction (anti-platelets/aspirin = 77.8%). Forty-one
percent had percutaneous coronary intervention and 8.8% received coronary artery
bypass grafting prior to participation in the study.
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3.3.2

Baseline clinical measures
Results of clinical assessments compared between groups at baseline including

global means of gray matter CBF and CVR are presented in Table 3.1. There were no
significant differences between patients and controls in terms blood pressure, left
ventricular function, resting heart rate and blood glucose. CAD patients had lower total
cholesterol (F = 15.34 (1, 53), p<0.0001) likely reflecting the therapeutic effect of the
combined drug therapy received by patients. However, CAD patients had lower MoCA
scores (F = 4.63 (1, 51), p<0.01) after adjustment for level of education, lower VO2max
(F = 15.02 (1, 37), p<0.0001), elevated BMI (F = 18.46 (1, 53), p<0.0001) and higher
carotid artery intima media thickness (F = 8.05 (1, 43), p<0.001). There was also a trend
of reduced carotid compliance in the carotid (p = 0.24) and elevated hs-CRP (p = 0.10), a
marker of inflammation and measure of myocardial infarction risk.
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Table 3.1: Study demographics
Controls

Patients

Body mass Index (kg/m2)

24.54 ± 3.11

29.84 ± 4.73*

Glucose (mmol/L)

4.72 ± 0.89

5.21 ± 1.38

Total cholesterol (mmol/L)

4.15 ± 0.96

3.09 ± 0.79*

hs-CRP (mg/L)

0.97 ± 0.91

2.10 ± 3.10

Systolic blood pressure (mm Hg)

120.28 ± 15.97

126.70 ± 21.20

Diastolic blood pressure (mm Hg)

68.18 ± 7.8

71.5 ± 12.41

Heart rate (beats per min)

58.34 ± 9.54

59.11 ± 6.85

Left ventricular ejection fraction (%)

67.41 ± 9.82

64.35 ± 7.24

Intima media thickness, carotid (mm)

0.53 ± 0.12

0.64 ± 0.12*

Compliance, carotid (mm/mm Hg)

0.0088 ± 0.003

0.0077 ± 0.003

MoCA

28.32 ± 1.67

26.82 ± 2.1*

VO2max (mL/kg/min)

37.27 ± 9.94

26.9 ± 7.24*

Resting PETCO2 (mm Hg)

43 ± 4

40 ± 6

ΔPETCO2 (mm Hg)

11 ± 3

13 ± 4

Global mean CBF (mL/100g/min)

50.83 ± 11.68

46.49 ± 13.88

Global mean CVR (mL/100g/min/mm Hg)

2.57 ± 0.62

2.26 ± 0.63

Variables

Means and standard deviations of clinical assessments compared between CAD patients
and controls. Statistical differences between groups at p<0.05 are indicated by *.
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3.3.3

Baseline brain imaging: Cardiac disease effects
The mean T1b across all subjects was 1562.6 ± 69.8ms. There was no difference

between T1b for patients and controls. Mean GM tSNR for the ASL-EPI sequence was
4.0 ± 1.4. Test-retest reliability of the CBF and CVR measurements performed voxelwise, showed no differences between trials (p <0.001, uncorrected). Because of the
reproducibility of GM CBF and CVR, CV = 6.4% for CBF and 14.9% for CVR with
corresponding ICC (2, 1) values of 0.93 and 0.82 for CBF and CVR respectively, ΔM
signals were averaged over the 2 trials. No differences were found in global mean CBF or
CVR between CAD patients and controls. Results from the multimodal voxel-wise
multivariate analysis are listed in table 3.2 and are represented graphically on a single
slice through the brain in figure 3.2. The results were as follows:
1) Eleven clusters were identified as having significantly lower CBF in the CAD
patients from the SPM exploratory step. The corresponding anatomical labels are
listed in table 3.2.
2) All eleven clusters remained significant after controlling for differences in GMV
between the two groups. However, the magnitude of the effect of disease on CBF
observed after atrophy correction was muted in nearly all regions, except in the
right anterior cingulate cortex and bilateral middle temporal gyri (table 3.2).
3) The cluster size of nearly all regions was also preserved after BPM ANCOVA
analysis except in the left precentral gyrus where the cluster size was reduced by
2 voxels.
4) Within the 11 regions, a significant decrease in GMV was observed in the CAD
group in the right and left superior frontal and in the left precentral gyri. These 3
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regions also had the greatest reductions in CBF changes following BPM analysis,
as indicated by reduced t-value (table 3.2).
In general, the brains of CAD patients had significant reductions in regional GM CBF
independent of GMV in the bilateral prefrontal, insula, middle temporal, superior
temporal, postcentral gyri, and in the right anterior cingulate cortex. Concomitant
decrease in GMV and atrophy-independent CBF were observed in the right and left
superior frontal, and in the left precentral gyri.
Between-group comparisons in regional CVR are shown in figure 3.3. Group
means from each cluster and the standard error of the means are displayed. Significant
decreases in CVR were observed in the CAD patients in the right anterior cingulate,
bilateral superior frontal gyri, right insular, right precentral gyrus, left superior
temporal/insula and left postcentral gyrus (all, p<0.05).
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Figure 3.2: Regions of interest analysis from voxelwise-comparisons.

Results of the region of interest analysis from voxel-wise comparisons between patients and controls;
in gray matter CBF from SPM and from BPM analysis, and comparisons in gray matter volume
derived from VBM. Clusters of significant difference between groups are depicted in yellow (p<0.05,
FDR, cluster threshold = 10 contiguous voxels) and overlaid on the axial, coronal and sagittal slices of
a single subject. The corresponding anatomical coordinates [x, y, z] are included.

Figure 3.3: Regions of differences in regional CVR compared between CAD patients
and controls at baseline.

Statistical differences between groups at p<0.05 are signified by * and error bars indicate standard
errors of the mean. R = right; L = left; SFG = superior frontal gyrus; ST = superior temporal gyrus;
Ins = insula; PostC = postcentral gyrus; MT = middle temporal gyrus; PreC = precentral gyrus; AC =
anterior cingulate.
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Table 3.2: Results of multimodal voxel-by-voxel multivariate analysis.
Talariach

Brain region

# of

coordinate

(Brodmann Area)

voxels

(X Y Z)

SPM

t

SPM
p

BPM t

BPM p

Regional gray matter CBF, controls > patients
1

L Superior temporal (41)

-34

-30

14

L Insula (13)

-38

-23

3

2

L Superior frontal (10)

-22

50

-1

3

R Anterior cingulate (24)

6

31

4

L Postcentral gyrus (3)

-38

5

R Postcentral gyrus (6)

6

5.64

0.01

5.20

<0.001

5.03

0.04

4.97

<0.001

63

5.11

0.01

4.57

<0.001

0

18

4.91

0.01

4.98

<0.001

-20

42

36

4.79

0.01

3.55

<0.001

53

-6

28

35

4.71

0.01

3.95

<0.001

R Middle temporal (39)

46

-62

20

57

4.47

0.02

4.50

<0.001

R Superior temporal (39)

55

-57

23

4.23

0.03

4.15

<0.001

7

R Insula (13)

36

-28

18

33

4.25

0.03

3.36

<0.001

8

R Superior frontal (10)

26

49

-1

21

4.21

0.03

3.23

0.002

L Precentral gyrus (4)

-55

-8

28

14

4.18

0.03

2.49

0.008

10

R Precentral gyrus (6)

46

-10

28

10

4.11

0.03

3.01

0.003

11

L Middle temporal (39)

-46

-69

16

18

3.61

0.04

3.69

<0.001

9

†
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VBM: Regional GMV, controls > patients
1

L Superior frontal (10)

-22

56

2

40

3.90

0.009

2

R Superior frontal (10)

26

54

2

21

3.88

0.009

3

L Precentral gyrus (4)

-56

-10

34

14

3.00

0.014

Results of regional voxel-by-voxel comparisons in regional CBF and in regional GMV between CAD
patients at baseline. Effect magnitude is represented by t-static from SPM analysis and from BPM
analysis, where changes in gray matter volume were accounted for. Results were corrected for
multiple comparisons (FDR, p<0.05). Coordinates of local maxima of clusters of significant difference
are listed and given in anatomical Talariach space. R = right; L = left; †for the left precentral gyrus, the
total number of voxels from BPM analysis was reduced to 12.

3.3.4

Cardiac rehabilitation effects
There were no differences within the CAD patient group in pre- and post-CR

clinical tests. Mean VO2 max at baseline and post-CR were 28.04 ± 10.47 mL/kg/min and
29.37 ± 8.74 mL/kg/min respectively. No difference in global mean gray matter perfusion
was observed before (46.4 ± 11.4 mL/100g/min) and after (50.0 ± 18.5 mL/100g/min)
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exercise training. Regional mean CBF at baseline and post-CR are shown in figure 3.4. A
significant increase in CBF (~30%) was seen post exercise in the right anterior cingulate
(p = 0.02), a region where a comparable decline in CBF compared to controls (~33%)
was observed at baseline, and a region where no change in GMV was observed after
exercise. An increase in GMV with exercise was found in the bilateral pre- and postcentral gyri and in the right superior frontal gyrus, while a sustained decrease in GMV
over time was seen in the left superior temporal and right insula regions.
Figure 3.4: Regions of differences in regional CBF compared in CAD patients
before and after CR.

Statistical differences at p<0.05 are signified by * and error bars indicate standard errors
of the mean. See figure 3.3 for full name of regions.

3.4

Discussion

There is a growing interest in the potential role of vascular disease in advancing
the age-related decline in cerebrovascular health and cognitive function. In a recent study,
we described marked brain atrophy spanning the frontal, temporal and parietal lobes of
CAD patients, and subsequent increase in brain volume with exercise1. Here, in the same
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cohort of CAD patients, accelerated cerebrovascular decline was observed in cognitive
areas of the brain. Interestingly, these changes were greater than the corresponding
declines in brain volume, suggesting that cerebral hypoperfusion associated with
cardiovascular disease could mediate neuronal volume loss. In addition, recovery of
perfusion in the right anterior cingulate was demonstrated after six months of exercise
training. These findings indicate that cardiovascular disease is associated with regional
cerebral hypoperfusion and diminished CVR, which indicate cerebrovascular dysfunction
and that these changes may be reversible with exercise.
Vascular aging is associated with increased plaque burden, impaired vascular
remodelling, arterial stiffness and endothelial dysfunction13, inducing perfusion deficits
that in turn decrease the amount of oxygen available for optimal tissue function13. In the
brain, for example by the age of 60, normal aging can reduce regional CBF by up to
15%14, offsetting the normal coupling of CBF to glucose metabolism14,15. This agerelated compromise in CBF is exacerbated by the presence of vascular disease, as
demonstrated by our findings and supported by previous observations6. Compared to agematched controls, we found decreased CBF in the brains of CAD patients in regions
known to be affected by various forms of vascular disease (for review see de la Torre6
and Friedman et al3). For instance, hypertension is associated with accelerated decline in
regional perfusion in the orbitofrontal, anterior cingulate and insular cortices16. In older
adults with various forms of cardiovascular disease, reductions in frontal and temporal
lobe CBF are associated with reduced regional cortical thickness and impairments in
memory, attention and executive functions17. The combined effect of vascular ageing and
high blood cholesterol leads to slow progression of atherosclerosis, where the narrowing
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of coronary, systemic or cerebral vessels can impede blood flow to the corresponding
tissue. With CAD, it is possible that subtle changes in blood supply to the brain could
pose an additional risk to the aging brain5, particularly in individuals with suspected
central arterial stenosis. We found significantly higher carotid intima media thickness, a
marker of generalized atherosclerosis18, in CAD patients compared to controls as well as
decreased carotid artery compliance. Increased carotid intima media thickness in older
adults, even in the absence of clinical vascular disease, is associated with regional
changes in CBF19, increased risk for AD18 and accelerated decline in performance on
tests for memory, language (semantic association fluency) and executive function, over
time20. Arterial stiffness, even at the level of the aorta7, and other vascular remodelling
responses to vascular disease impair CVR21, ultimately affecting higher-order cognitive
processes.
CVR was significantly reduced in CAD patients in multiple regions including the
anterior cingulate, superior frontal and postcentral gyrus. Typically, CBF reductions are
likely either a result of reduced supply to tissue, signifying vascular dysfunction, or a
result of reduced metabolic demand, signifying a decline in neuronal activity. The
observed reduction in CVR in areas of reduced CBF in the CAD patients supports the
former since it indicates that the brain's vascular response to a vasoactive stimulus was
impaired, which suggests that the CBF response to increased functional activation may
also be impaired22.
The decline in cognitive abilities in domains of executive function, attention,
language, memory and visuospatial skills seen in vascular disease patients, independent
of normal aging effects23, is consistent with the regional pattern of decreased resting CBF
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and CVR observed in these CAD patients. Interestingly, these patients also had lower
MoCA scores compared to controls, after adjusting for level of education. Impaired CVR
is associated with a decline in global cognitive function in dementia patients24 and could
reveal cognitive dysfunction sooner and with greater sensitivity than resting CBF. Lu et
al25 demonstrated that CVR in the prefrontal cortex showed an accelerated decline with
age compared to CBF. These observations underscore the significance of CVR as a
marker of cerebrovascular health and potentially of cognitive function in cardiovascular
disease patients.
One of the main findings of the current study was the observation of differences
in the spatial patterns of hypoperfusion and brain atrophy in the CAD patients. Of the 11
clusters identified as having lower basal CBF, only 3 clusters- all within the prefrontal
cortex- showed a concurrent decrease in GMV following BPM analysis. A spatial
mismatch between regional hypoperfusion and atrophy has also been observed in normal
aging26. These observations suggest that certain areas of the brain respond differently to
hemodynamic and structural changes associated with aging and vascular disease. It is
also possible that the CBF changes observed in CAD patients could precede structural
changes. It is important to consider that the poor spatial resolution of ASL compared to
structural imaging could lead to partial volume errors. To minimize this, differences in
CBF between patients and controls were only conducted in voxels that were classified as
being comprised of at least 80% gray matter, followed by BPM analysis to control for
changes in GMV. An alternative approach would be to use linear regression methods
such as outlined by Asllani et al27 to extract a GM CBF image. However, this approach
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can introduce substantial spatial blurring, which when applied to regions as small as those
identified in the current study, could eliminate the observed effects.
Another notable finding of the current study was the recovery of CBF in the right
anterior cingulate after mild-to-moderate aerobic fitness training. This finding agrees
with a previous study that reported higher CBF in the anterior cingulate cortex in
aerobically-trained older adults compared to sedentary controls28. A positive correlation
between CBF in the anterior cingulate and VO2max has also been reported in CAD
patients29. Similar to Chapman et al28, we observed no increase in global CBF after
exercise training; however, the effects of exercise on global CBF are conflicting30.
Conversely, Colcombe et al associated the level of aerobic fitness with decreased activity
in the anterior cingulate and increased activity in the middle frontal, superior frontal and
parietal regions in older adults performing conflicting response tasks31. Though they
attributed their observation to improved adaptations in the attentional network following
exercise training31, it could also signify the effects of exercise in enhancing both
cognitive and cardiovascular control32. Decreased activity in the anterior cingulate
(subgenual) and medial prefrontal cortex along with increased activity in the insular
cortex, are strongly associated with cardiovascular adjustments to acute stressors during
physical, cognitive and emotional demands32. Although we did not find significant
changes in CBF in the insular or prefrontal regions after exercise training, we previously
reported increased brain volume in the medial prefrontal region in addition to other
cognitive areas1. Increased volume in the prefrontal, anterior cingulate and medial
temporal lobes are consistently associated with improved higher cardiorespiratory fitness
level33. It is possible that one of the mechanisms by which aerobic fitness training
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improves cardiovascular function is the augmentation of cortical control of
cardiovascular homeostasis. We were unable to investigate regional CVR response to
exercise training given the relatively small sample, a global increase in CVR has been
reported in older adults following 12 weeks of mild-to-moderate aerobic exercise34 and in
stroke patients35 after completing a 6-month exercise program. In general, our findings of
recovery of regional CBF following cardiac rehabilitation continue to support the role of
aerobic fitness in preservation of brain health following injury.

3.4.1

Study considerations
The findings presented in the current study although largely attributed to coronary

artery disease, could also be associated with lifestyle factors3. Compared to controls,
CAD patients had significantly lower fitness levels and were generally overweight. The
effect of these lifestyle factors on cerebral perfusion and brain structure in the presence of
vascular disease are yet to be determined. A large majority of the CAD patients were on
antihypertensive and hypolipidemic drug. These agents are known to affect
cerebrovascular hemodynamics and could mask vascular disease effects or attenuate
exercise effects. Stains for instance are hypolipidemic agents associated with increased
CBF and vascular reactivity36, while antihypertensive drugs such as beta-blockers can
limit submaximal exercise capacity37. Furthermore, we did not explore potential ongoing
cerebrovascular disease in the study population, specifically, white matter lesions, which
could further contribute to cerebral hypoperfusion and atrophy. Our analysis, however,
focused on vascular disease effects within gray matter. Areas associated with white
matter hyperintensities are typically deep within white matter regions.
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Other study considerations include the inherent limitations with the ASL imaging
and the hypercapnic challenge. First, the 2D EPI readout used in this study for ASL
imaging, limited data acquisition to slices superior to the anterior commissure - posterior
commissure line. As such, regions near tissue-air/bone interfaces prone to increased
susceptibility artefacts were excluded. Cerebral hypoperfusion may well exist in the
inferior regions of the frontal and parietal lobes, since brain atrophy has been observed in
these regions in the same cohort of CAD patients1. Second, our choice of post-labelling
delay was relatively short. It was selected to mediate the effects of short arterial transit
time at high flow velocities during hypercapnia and increase SNR. This resulted in a
tSNR comparable to newer ASL methods using three-dimensional gradient-spin echo38
readouts, where whole brain coverage can be achieved at longer post-label delay and
minimal susceptibility issues. A short post-labelling delay could result in an
underestimation of CBF in patients with longer transit times, however no watershed
artifacts, which are typical of transit time errors, were observed in the CBF images.
Lastly, the CVR results were limited by a small sample size due to poor compliance with
the hypercapnic manipulations, compounded by inter-subject variability in ventilation
response during CO2 inhalation. Reproducible changes in PETCO2 were achieved by
controlling the respiration rate using a metronome. However, commercial devices
designed to control PETCO2 breath by breath, such as the RespirAct (Thornhill Research,
Toronto, Canada) would improve the sensitivity of CVR measurements.
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3.4.2

Conclusion
This study represents a concerted attempt within a single cohort to

investigate the association between cardiovascular disease and cerebral hemodynamics,
as well as investigating the potential benefits of physical activity. The findings
demonstrated a region-specific vulnerability to cardiovascular disease that appeared to
accelerate the normal changes in CBF associated with aging. It is possible that reductions
in regional CBF and CVR, related to vascular disease could drive cortical decline.
However, the fundamental mechanisms underlining the association between vascular
disease and cortical decline remain unclear and require further investigation. The ability
of an aerobic fitness program designed for CAD patients to improve cerebral perfusion
was demonstrated in a relatively small sample. This work sets the stage for future
investigations in larger cohorts of vascular disease patients to understand how
cardiopulmonary fitness training impacts cerebrovascular hemodynamics.
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Chapter 4

Feasibility of Simultaneous Whole-brain Imaging of Cerebral Perfusion
and Glucose Metabolism on a Whole-body Integrated PET-MRI
Scanner.
The chapter is adapted from the paper entitled "Feasibility of simultaneous whole-brain
imaging on an integrated PET-MRI system using an enhanced 2-point Dixon attenuation
correction method", published in Frontiers in Neuroscience, 2015; (8) :434, by Udunna C
Anazodo, Jonathan D Thiessen, Tracy Ssali, Jonathan Mandel, Matthias Günther, John
Butler, William Pavlosky, Frank S Prato, R Terry Thompson, and Keith S St. Lawrence.
It is reproduced here under a Creative Commons Attribution CC-BY license.

4.1

Introduction

Multimodal imaging approaches that simultaneously pull together structural,
functional and molecular information have the potential to improve the characterization
of normal and/or abnormal neurophysiology. The development of positron emission
tomography (PET) and magnetic resonance imaging (MRI) hybrid systems provide the
combined advantages of high molecular sensitivity of PET and high spatial resolution of
MRI, among other benefits. The clinical potential of this hybrid approach extends beyond
image fusion considering the ability of MRI to collect data associated with not only
anatomy but also function, diffusion and metabolite concentrations1, thereby maximizing
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diagnostic accuracy2 as image registration errors and total image acquisition times are
minimized, and physiological and metabolic states are identical.
However, accurate correction of PET signal attenuation in PET-MRI hybrid
systems using information derived from MRI is challenging. Inherent limitation(s) of
various proposed attenuation correction methods can lead to PET quantification errors of
up to 20%3–6, which limits adoption of PET-MRI in neuroimaging. Commercial PETMRI hybrid systems rely on MRI-derived attenuation correction (MRAC) using a 2-point
Dixon method7 based on segmentation of MR signals from water and fat into air, lung, fat
and soft tissue8 but ignores bone, rendering this method less ideal for brain imaging.
Various methods have been explored to produce optimal MRAC maps for neuroimaging
that are as accurate as clinically accepted AC maps produced by computed tomography
(CT). Ultra-short echo (UTE) MRI9 where bone is imaged and incorporated into AC
maps, can suffer from low spatial resolution and inaccurate signal segmentation4.
Methods that employ CT templates/atlases mapped to individual MRI10,11 or to guide
MRI segmentation12–14, require complex algorithms that have limited reproducibility and
at best still retain some level of inter-modality misregistration15, especially where large
signal intensity differences exist between MRI and CT (e.g. cortical bone).
In this study we explored the feasibility of hybrid PET-MRI systems in
simultaneous measurements of brain function with PET and MRI using an enhanced
Dixon-based MRAC for PET signal attenuation correction in an integrated PET-MRI
system. Simultaneous functional imaging was achieved by combining 3-dimensional
(3D) pseudo-continuous arterial spin labelling (pCASL) with

18

F-fluoro-deoxyglucose

(FDG) PET since FDG is considered a suitable surrogate marker of brain function 16 and
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pCASL is a reliable MR perfusion method for assessment of brain function under resting
and task-induced conditions in normal and disease states17. The goal was to investigate if
regional correlations in relative cerebral blood flow (rCBF) to relative cerebral rate of
glucose consumption (rCMRglc) measured with a hybrid PET-MRI scanner were
comparable to previous studies using either PET alone18 or separate PET and MRI
systems19. If successful, the obvious advantage is that future studies in neuropsychiatry or
neurodegeneration, for instance, could correlate perfusion MRI to disease-specific PET
tracers for better characterization of disease expression20. The proposed enhanced Dixon
MRAC combines bone segmentation from high-resolution 3D T1-weighted anatomical
images, routinely acquired in brain imaging, with the standard Dixon MRAC method
implemented by the manufacturer. Comparison between the Dixon and enhanced Dixon
method was made across a number of brain regions to assess regional differences and
performance.

4.2
4.2.1

Materials and Methods
Participants

This study was approved by the University Research Ethics Board, and written
informed consent was obtained from all subjects. PET-MRI images were acquired from
oncology patients recruited following the completion of a clinical PET-CT exam as part
of their healthcare management. A total of 13 oncology patients were recruited 7 males
and 6 females (58 ± 8 years old). All subjects had no history of neurological disorder and
no radiation therapy or chemotherapy prior to imaging and were referred for whole-body
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PET-CT exam for staging of oncology. To minimize errors in MRI image quality from
potential image artifacts produced by metal implants such as MR signal loss, only
patients free of metallic implants and fixtures including dental implants were included in
this study.

4.2.2

PET-MRI image acquisition
Whole-brain PET and MRI data were acquired simultaneously on a Siemens

Biograph® mMR system. The PET subsystem consisted of 8 rings of 56 detector blocks,
each housing 8 x 8 LSO crystals (size = 4 x 4 x 20 mm3) coupled to 3 x 3 array of APDs
producing a transaxial field of view (FOV) of 59.4 cm and an axial FOV of 25.8 cm. The
3T MRI subsystem is similar to a Siemens 3T Verio with a maximum gradient strength of
45 mT/m and slew rate of 200 T/m/s, but a reduced bore size of 60 cm. For detailed
description of the Biograph® mMR specifications cf. Delso et al. 201121. All MR images
were acquired using a PET-compatible 16-channel phased array head (12-channel) and
neck (4-channel) radiofrequency (RF) coil.
PET-MRI data were acquired immediately following the completion of 20 minute
whole-body PET-CT imaging and following a 60-minute uptake of a bolus FDG
intravenous injection (5 MBq/Kg) administered in a dim lit room. All subjects fasted for
a minimum of 6 hours and had blood glucose level between 4.8 to 5.8 mmol/L. Clinical
whole-body PET-CT were acquired following standard oncology imaging protocol from
the level of the eyes to the mid-thigh. A series of MR images were acquired during a 15
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minute PET list-mode acquisition with subjects in supine position. The MRI data
included:
a) Coronal T1-weighted dual-echo 3D VIBE-Dixon for MRI Dixon-based
attenuation correction of PET data (repetition time (TR) = 3.60ms, echo times
(TE) =1.23 and 2.46ms, flip angle = 10°, FOV = 500 x 328mm2, 128 slices, voxel
size = 4.1 x 2.6 x 3.1mm3, bandwidth = 965 Hz/Px, acceleration factor of 2, and
total acquisition (TA) = 0.19s) 22;
b) Sagittal T1-weighted 3D magnetization-prepared rapid gradient-echo (MPRAGE)
sequence (TR/TE: 2000/2.98ms, inversion time (TI) = 900ms, flip angle = 9°,
FOV = 256 x 256mm2, 176 slices, isotropic voxel size = 1.0 mm3, bandwidth =
240 Hz/Px, an acceleration factor of 2 and TA = 4.48min);
c) Transverse 3D single shot gradient-and-spin-echo (GRASE) pCASL sequence

23

(TR/TE = 3500/22.76ms, FOV = 240 x 240 mm2, 24 slices, voxel size = 3.8 x 3.8
x 5mm3, bandwidth = 2298 Hz/Px, and acceleration factor of 2). The pCASL label
consisted of 1.5s train of RF pulses applied 9cm below the center of the imaging
volume with a mean gradient of 0.6 mT/m. Sixty-four label and control pairs were
acquired after a post-label delay of 1.2 s for TA = 7 min. Two nonselective
inversion pulses were applied for background suppression during the post-labeling
delay. Proton density images (M0) were acquired with the pCASL sequences for
CBF quantification using a TR of 5 s, with no labeling or background suppression
pulses.
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4.2.3

MR attenuation map (µ-map) generation and PET image
reconstruction.

Two MRAC segmentation methods were used for attenuation correction of the
PET data: the standard 2-point Dixon method22 and 2-point Dixon method plus bone
segmentation (Dixon+bone), which is described below. The Dixon MRAC µmaps were
generated online from segmentation of fat and water signals in the in- and out-of-phase
Dixon images into fat, soft tissue and air/background, as implemented by the
manufacturer. Linear attenuation coefficients of 0 cm-1, 0.086 cm-1 and 0.10 cm-1 were
assigned to air, fat and soft tissue, respectively

22

. Attenuation correction factors for

hardware including the RF coil and scanning bed were included in the Dixon µ-map. The
Dixon+bone

MRAC

µ-maps

were

generated

offline

using

SPM8

(http://www.fil.ion.ucl.ac.uk) and in-house MATLAB (2012a, The MathWorks, Natick,
MA) scripts. This method overlays a bone mask created from bone segmentation of the
MPRAGE image to a Dixon µ-map and applies a linear attenuation coefficient (µa) of
0.143cm-1 9, the µa value of bone at 511kev, to the bone mask.
The bone mask for each subject was created as follows. 1) The T1-weighted
MRPAGE dataset was coregistered to the Dixon in-phase image in SPM8 using rigidbody transformation with a normalized mutual information cost function to place the
MPRAGE in the same voxel space as the Dixon µ-map. 2) The coregistered MPRAGE
image set was segmented into gray matter, white matter, cerebrospinal fluid, bone, soft
tissue and air/background probability tissue maps in native space using the new segment
function

in

SPM8

and

ICBM

Tissue

Probabilistic

Atlases

(http://www.loni.usc.edu/ICBM/). The new segment toolbox employs the unified
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segmentation method

24

that combines affine registration to ICBM atlas, bias field

correction and segmentation within one integrated model. 3) The bone probability map
was down-sampled to the Dixon images matrix size, smoothed with a 4 mm Gaussian
filter

25

and thresholded for probabilities above 80% to minimize inclusion of non-bone

signals. 4) The resulting binary image was eroded with morphological filtering and
connected component analysis using a 3x3x3 voxel size of ones before assigning µa of
0.143cm-1. Erosion was performed to minimize inclusion of non-bone voxels and the size
of the structure elements were determined after empirical evaluation of bone voxels
within a region known to have true bone content.
Each subject's PET list-mode data were reconstructed using the Siemens e7 tools
to one image volume 344 x 344 x 127 matrix with an iterative algorithm (ordered-subsets
expectation maximization: 3 iterations, 21 subsets; 3D Gaussian filter with a full width
half maximum (FWHM) = 2.0 mm and 2.5 zoom factor) and corrected for decay, dead
time, scatter and attenuation. The reconstruction was performed twice using either the
Dixon (PETdx) or the Dixon+bone (PETdxbone) MRAC µ-map.

4.2.4

Image Analysis
To allow for group comparison between PETdx and PETdxbone, the PET images

were spatially normalized to the Montreal Neurological Institute (MNI) PET template in
SPM8 (http://www.fil.ion.ucl.ac.uk) using an affine transformation and non-linear warps,
and smoothed with a 6-mm FWHM Gaussian filter. The gray matter (GM) probability
map for each subject was spatially normalized to the T1 MNI template using the unified
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segment approach in SPM, also smoothed with a 6-mm Gaussian filter, transformed to a
binary mask at a threshold of 80% and applied to the PETdx and PETdxbone images.
The difference between the Dixon+bone and the Dixon MRAC method across the
brain was computed as the percent relative difference (% RD) in mean activity
concentration

(Bq/ml)

in

thirteen

a

priori

regions

of

interest

(ROIs).

 ( PET dxbone  PET dx ) 
% RD  
  100 . ROI brain masks were created using the automated
PET dx



anatomical library

26

incorporated within WFU PickAtlas toolbox version 3.0

27

. The

ROIs were frontal lobe, cingulate gyrus, insula, parietal lobe, temporal lobe,
hippocampus, amygdala, thalamus, caudate, globus pallidus, putamen, and cerebellum.
The PETdx and PETdxbone images were scaled by their respective global gray matter mean
value to allow for voxel-by-voxel comparison between glucose uptake and blood flow,
and since absolute quantification of PET-FDG with tracer kinetic modeling was not
feasible in this study and generally not feasible in clinical practice. Regional %RD in
relative mean activity was also calculated in the scaled PET data (rPET). To investigate
potential regional differences, the mean values extracted from individual ROIs were
compared between the two PET data sets using paired t-tests with SPSS 20.0 statistical
software (IBM Corp. Armonk, NY, USA). Statistical significant differences were set at
threshold p-value <0.05.
pCASL preprocessing was performed with SPM8 and scripts written in
MATLAB. The pCASL time series were motion corrected, pair-wise subtracted, and
time-averaged. The mean signal was registered to the MPRAGE images using a rigidbody transformation and converted to CBF using a single-compartment flow model
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.

The CBF images were spatially normalized to the MNI template and smoothed using a
Gaussian filter with a FWHM of 6 mm. A GM mask was applied to the CBF images that
were normalized by the global mean. To determine the temporal signal-to-noise ratio
(tSNR) of the perfusion-weighted time series when acquired with a PET-compatible head
coil, tSNR was calculated for each subject as defined by the mean pixel signal in the
whole brain relative to the mean pixel standard deviation.
Whole brain voxel-by-voxel independent samples t-tests restricted within a GM
mask were performed on the individual relative images in SPM8 to investigate
differences between rCBF and rPET images. Statistical significant differences were
identified for clusters greater than 50 voxels at p <0.05 after correcting for multiple
comparisons using the False Discovery Rate (FDR). Voxel-by-voxel Pearson correlation
was conducted on relative images averaged across subjects within the thirteen ROIs to
correlate rCBF to rPETdx and to rPETdxbone.

4.3
4.3.1

Results
Study Participants

A full description of the study demographics is listed in Table 4.1, including age,
gender and diagnosis. No neurological lesions or gross neuropathological abnormalities
were observed on PET-MRI brain images. Images were reviewed by a Board Certified
Radiologist and Nuclear Medicine physician. Mean and standard deviation of the time
from FDG injection to PET-MR examinations were 103 ± 11.18 minutes.
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Table 4.1: Study Demographics.
Number
1
2
3
4
5
6
7
8
9
10
11
12
13

Age (years)
62
55
39
64
62
62
54
51
56
65
61
71
53

Gender
F
M
M
M
F
F
M
F
M
F
F
M
M

Primary oncology disease
SPN
SPN
Germ Cell (Testicular)
SPN
SPN
SPN
SPN
SPN
SPN
Colorectal
NSCLC
SPN
NSCLC

Net Injected Dose (MBq)
368
390
500
422
288
229
437
200
418
337
411
388
396

SPN = Solitary Pulmonary Nodule, NSCLC = non-Small cell lung cancer, M= Male, F=Female.

4.3.2

Evaluation of MRAC methods.
An example of Dixon+bone µ-map created by adding bone to a Dixon µ-map

from a representative subject is displayed in Figure 4.1. A gradual radial increase in
relative difference between PET images reconstructed with Dixon+bone µ-map compared
to Dixon µ-map were observed in all subjects. Figure 4.2a, illustrates the typical line
profile (Figure 4.2b) through the center slice of the brain of one subject when the PETdx
and PETdxbone images are compared. An increase of 5% in the center to nearly 20% in the
areas around the cortex was seen.
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Figure 4.1: Illustration of a Dixon+bone µ-map generated in a representative
subject.

Images (A) T1-weighted MPRAGE, (B) bone probability map, (C) Dixon µ-map and (D)
Dixon+bone µ-map are shown in axial, coronal and sagittal views of a single slice.

Group mean values and standard deviation of absolute and relative activity in
PETdx and PETdxbone for whole brain and regions of interest are listed in Table 4.2. Paired
student t-test showed that the absolute mean activity in PET data reconstructed with
Dixon+bone µ-map was statistically higher than PET reconstruction with Dixon µ-map in
all thirteen ROIs. Conversely, lower relative activity was found in rPETdxbone when
compared to rPETdx in all ROIs except, occipital and cerebellum. These regional
differences are depicted in Figure 4.3a as the percent relative difference in mean activity
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between PETdx and PETdxbone, and in Figure 4.3b as the percent relative difference in
rPETdx and rPETdxbone for all thirteen ROIs.
Figure 4.2: Line profile

Line profile (A) across the center slice of a map (B) of relative difference (% RD) between PET
images reconstructed with Dixon and Dixon+bone µ-maps. Images are presented from a
representative subject.

Figure 4.3: Regions of interest group means percent relative difference (% RD).

%RD in (A) mean activity concentration and (B) mean relative activity between PET signals
reconstructed with Dixon and Dixon+bone µ-maps. Errors bars represent standard deviation on the
means. Regions abbreviations: Fro = Frontal, Cng = Cingulate, Ins = Insula, Par = Parietal, Tem =
Temporal, Hpp = Hippocampus, Amg = Amygdala, Cad = Caudate, Pal = Globus Pallidus, Put =
Putamen, Occ = Occipital and Ceb = Cerebellum.
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Table 4.2: Group mean and standard deviation (std) of absolute and relative PETdx
and PETdxbone activity concentration (kBq/ml) in regions of interest across the
brain.
Absolute mean activity
PETdx

Relative mean activity

PETdxbone

PETdx

PETdxbone

Region

Mean

std

mean

std

T

mean

std

mean

Std

t

Frontal

12. 70

2.60

14.12

2.86

15.21

0.96

0.04

0.97

0.03

2.95*

Cingulate

13.90

2.88

14.88

3.04

17.74

1.06

0.05

1.02

0.05

-22.66

Insula

13.47

2.35

14.39

2.50

17.08

1.03

0.04

0.99

0.04

-24.74

Parietal

13.49

2.71

14.91

2.97

16.99

1.03

0.03

1.02

0.03

-0.74*

Temporal

11.63

2.26

12.84

2.51

15.11

0.88

0.02

0.88

0.02

-2.01*

Hippocampus

10.35

1.85

10.93

1.97

14.21

0.79

0.05

0.75

0.05

-32.13

Amygdala

10.42

1.87

11.03

2.01

13.53

0.80

0.07

0.76

0.07

-26.43

Thalamus

14.11

2.77

14.87

2.92

13.91

1.07

0.06

1.02

0.06

-34.88

Caduate

11.33

3.10

11.90

3.24

12.47

0.85

0.09

0.81

0.09

-29.34

Pallidum

14.23

2.66

15.02

2.83

12.93

1.08

0.07

1.03

0.07

-36.10

Putamen

16.83

3.21

17.91

3.43

14.21

1.28

0.08

1.23

0.08

-31.08

Occipital

13.18

2.63

14.87

2.95

16.90

1.00

0.06

1.02

0.07

5.74

Cerebellum

10.68

1.78

11.97

2.03

16.46

0.82

0.08

0.83

0.08

5.36

Whole brain

13.16

2.56

14.56

2.81

17.82

1.04

0.10

1.07

0.10

3.05*

Results of paired differences between PETdx and PETdxbone are presented as value of the t-statistic (t),
where all regional differences met the statistical threshold of p<0.05 except for * where p value >0.05.

4.3.3

Correlations of perfusion to glucose uptake
Images of relative CBF, PETdx and PETdxbone averaged across all subjects are

displayed in Figure 4.4. In general, these group-wise images are similar in appearance.
On visual inspection, the group-averaged PET data reconstructed with Dixon+bone µmap had an apparent higher intensity compared to PET data reconstructed with Dixon µmap, particularly around the cortex. An additional difference between the data sets was
the aliasing artifact observed in the CBF images, which are most visible in distal images.
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The mean group gray matter CBF was 43.82 ± 4.46 ml/100g/min. The mean tSNR of
whole brain pCASL signal in gray matter across all subjects was 2.83 ± 1.18.

Figure 4.4: Whole-brain group maps of relative perfusion and relative glucose
uptake.

Whole-brain group maps from; left to right: pCASL-CBF, FDG-PET reconstructed with Dixon+bone
MRAC and FDG-PET reconstructed with Dixon MRAC. Spatial blurring seen in the bottom row
images of the perfusion maps could be minimized with segmented multi-shot 3D GRASE
acquisitions.

The average voxel-by-voxel correlation coefficient across whole-brain grey
matter was r= 0.63 (p<0.001) between rCBF and rPETdx, and r= 0.53 (p<0.001) between
rCBF and rPETdxbone. The correlation coefficient for each ROI, derived from voxel-wise
comparison between rCBF and rPETdx and between rCBF and rPETdxbone, are presented
in Table 4.3 along with corresponding total number of voxels. For the comparison
between rCBF and rPETdx, moderate-to-high correlations were observed in all ROIs with
the highest in the caudate and the lowest in the deep-lying structures of the limbic system
such as the hippocampus and amygdala.

152

Figure 4.5: Whole brain voxel-by-voxel comparison between rCBF and rCMRglc

Comparison between relative cerebral blood flow and relative FDG-PET activity reconstructed with
Dixon (A) and Dixon+bone (B) µ-maps. Areas with greater relative perfusion are shown in red while
areas with greater relative glucose uptake are shown in blue. Statistical differences are set at threshold
for cluster > 50 voxels, p <0.05 corrected for multiple comparisons with FDR.

Similar trends were observed between rCBF and rPETdxbone. Results of voxel-byvoxel independent samples t-test listed on Table 4.4, showed areas of significant increase
or decrease in relative perfusion compared to relative FDG-PET signals reconstructed
with Dixon and with Dixon+bone µ-maps for clusters that met the set statistical
threshold. Maps of statistical differences between rCBF and either rPETdx or PETdxbone overlaid on axial slices of a single subject T1-weighted image are displayed in Figure 4.5.
Regions with higher relative perfusion are marked in red while regions with higher
relative glucose uptake are marked in blue.
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Table 4.3: Results of voxel-by-voxel Pearson correlation within thirteen regions of
interest.
rCBF vs. PETCT
(Cha et al.,
2013)

ROI

ke

rCBF vs. rPETdx

rCBF vs.
rPETdxbone

Frontal

70169

0.61

0.52

0.41

Cingulate

7598

0.77

0.76

0.61

Insula

3541

0.54

0.53

0.63

Parietal

26845

0.63

0.58

0.5

Temporal

32962

0.72

0.63

0.67

Hippocampus

1797

0.43

0.41

-0.26

Amygdala

414

0.42

0.40

0.087

Thalamus

2149

0.68

0.68

0.45

Caudate

1895

0.85

0.85

0.78

Pallidum

573

0.41

0.41

Not measured

Putamen

2009

0.48

0.46

0.81

Occipital

21333

0.82

0.73

0.12

Cerebellum

21838

0.54

0.46

0.33

Correlation coefficients (r, p<0.001) are listed for comparisons between relative ASL-CBF and
relative PET-FDG measurements corrected with Dixon and Dixon+bone µ-maps, and comparisons
from a previous study using 2D-pCASL sequence and PET-CT. Total number of voxels (ke) within
each ROI for the MRAC comparisons are included.
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Table 4.4: Results of independent samples t-test in gray matter comparing rCBF to
rPET.
Cluster number
rPETdx > rCBF
1
2
3
4
5
6
7
8
9
rPETdx < rCBF
1
2
3
4
5
6
7
rPETdxbone > rCBF
1

Cluster
size

X

y

z

t-value

Anatomical label

431
435
1591
457
569
685
126
61
126

-22
28
16
66
26
-20
-44
22
20

12
8
34
-52
-14
-54
-24
-90
-54

-8
-6
-28
-18
68
68
-32
-16
70

8.67
7.84
5.38
4.88
4.26
4.25
4.23
4.16
3.71

Left putamen
Right putamen
Right orbital frontal
Right inferior temporal
Right precentral
Left postcentral
Left inferior temporal
Right occipital
Right postcentral

1773
7935
6368
947
268
59
77

0
62
-56
-4
4
-2
14

-22
-34
-28
42
-74
-86
-28

42
10
24
-4
0
14
6

6.91
6.90
6.24
5.73
4.92
4.55
3.59

Left paracentral
Right superior temporal
Left inferior parietal
Left anterior cingulate
Right lingual
Left cuneus
Right thalamus

650

26
-24
16
66
66
26
-20
-18
26
4
20
-20

8
6
34
-52
-58
-14
-36
-38
-16
-34
-6
-72

-6
-6
-28
-18
6
68
58
38
-32
-12
20
16

7.9
7.8
6.10
5.71
5.63
5.25
5.05
4.21
4.09
3.77
3.61
3.58

Right putamen
Left putamen
Right orbital frontal
Right inferior temporal
Right middle temporal
Right precentral
Left postcentral
Left cingulate
Right parahippocampal
Right anterior cingulate
Right caudate
Left precuneus

2
3

1591
1332

4
5
6
7
8
9
10

4373
2848
65
79
83
70
76

rPETdxbone< rCBF
1

1318

62
-34
12
6.14
Right superior temporal
62
-28
2
5.52
Right middle temporal
2
630
0
-22
44
5.91
Left paracentral
3
668
-62
-38
48
5.16
Left middle temporal
4
238
48
10
18
4.88
Right inferior frontal
5
210
-48
-60
34
4.79
Left angular
6
72
4
-72
18
4.57
Right cuneus
7
73
-46
30
4
4.25
Left inferior frontal
8
82
-44
10
18
4.15
Left insula
9
186
6
42
-8
3.87
Right medial frontal
Results of independent samples t-test in gray matter comparing rCBF to rPET dx and comparing rCBF to
rPETdxbone for clusters > 50 voxels (p<0.05, FDR). MNI coordinates (x, y and z) and corresponding
anatomical location are included.
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4.4

Discussion

The feasibility of an integrated whole-body PET-MRI system in simultaneous
acquisition of perfusion MRI and metabolic PET neuroimaging with an enhanced
attenuation correction method was investigated in this study. Following efforts by other
groups to minimize errors in PET signal attenuation corrected with MRI9,13,14,29, and
given the lack of consensus on acceptable MRAC methods for bone attenuation30, we
explored a practical workaround for MRAC. Regional correlates of relative cerebral
glucose consumption acquired with FDG-PET, to relative cerebral perfusion acquired
with pCASL were also explored. In general, a good correlation between perfusion and
glucose consumption was observed over the entire brain, but regional variability in
coupling was observed, with the highest correlation in the occipital, and the lowest in the
striatum structures.
Direct segmentation of high resolution T1-weighted MR data into various tissue
classes for MR attenuation correction of PET have been proposed by Zaidi et al31 and
Wagenknecht et al32. Segmentation of voxel intensities were performed with
sophisticated algorithms that use fuzzy clustering or a priori knowledge of tissue location
and shape to derive MRAC μ-maps with ~6% maximum absolute relative difference
compared to ground truth25,31. However, these methods are time consuming, require postprocessing algorithms that are not readily available, and in Zaidi et al's method31; require
user intervention to improve bone segmentation. In addition, these proposed approaches
are sensitive to MR intensity inhomogeneity errors which, when left unaccounted for can
exacerbate inherent MR signal issues such as partial volume effects and motion artifacts,
potentially inflating bias in MRAC μ-maps. In this study, bone segmentation of T1156

weighted data was easily derived with SPM, an automated pipeline routinely used for
brain segmentation in neuroimaging. For each voxel, the unified segmentation method in
SPM determines intensity distributions of tissue types using a mixed model cluster
analysis and spatial priors from a T1-weighted atlas derived from large number of
subjects24. Unlike aforementioned direct segmentation methods, the unified method
accounts for non-uniformities in intensity distributions, improving segmentation
accuracy33.
In general, a ~10% increase in whole brain mean FDG activity corrected with
Dixon+bone compared to standard Dixon MRAC was observed. A gradual increase in
mean FDG activity from ~5% in the center to ~20% in the cortex was observed in PET
data corrected with Dixon+bone compared to the same PET data corrected with just
Dixon alone, as illustrated in Figure 4.2 for one individual. This finding was consistent
with a recent study comparing PET images corrected with the standard Dixon method to
images corrected with Dixon plus bone information derived from individual CT3. In this
study, Andersen et al3 reported a 15% difference in mean activity from the center to the
edge of the brain in PET signal reconstructed with Dixon compared to Dixon plus CT
bone. Errors caused by not including bone information are more pronounced at the edge
than the center of the brain as photons from the edge of the brain travel longer average
path lengths through skull than photons from the center3.
Regional variability in mean activity between PETdx and PETdxbone was also
observed in the ROI analysis. Cortical structures such as frontal and temporal lobe had
significantly higher relative differences than central brain regions such as basal ganglia
and limbic systems (Figure 4.3a). All thirteen brain regions investigated had statistically
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significant lower mean activity when reconstructed with the standard Dixon compared to
the reconstruction with the Dixon plus bone (Table 4.2). Similar regional variability in
PET-corrected with standard Dixon MRAC compared to CT attenuation maps have
recently been observed by other groups4,5. Scaling the PET images by their global mean
removed the overall underestimation but resulted in regional over- and under-estimations
(Figure 4.3b). These regional trends matched results from a previous study4 and indicate
that irrespective of the chosen reference region, cerebellum4 or global mean as used in the
current study, relative PET measurements reconstructed with Dixon still possess MRACrelated bias, albeit slightly reduced. Although signal normalization to a reference value
can reduce systemic errors in PET reconstruction, it can inflate regional values
particularly in cases where group differences actually exist between the reference
values34. This might explain the apparent increase in relative PET activity with standard
Dixon compared to Dixon+bone (table 4.2) or UTE4 in nearly all regions of the brain.
Altogether, the results are in line with previous studies showing that the addition of bone
information, either from MRI (UTE/MPRAGE) or CT, to the MRAC maps removes the
radial bias3 and reduces differences in PET signals from ~20 % to 10% when compared
to the gold standard, CTAC4,9,11,14.
The clinical significance of incorporating bone attenuation in PET reconstruction
was highlighted by correlating relative cerebral glucose uptake acquired with FDG-PET
to relative cerebral perfusion acquired with pCASL across regions in the brain. Recent
evidence suggest that a pattern of regional distribution of perfusion to glucose
metabolism exist in healthy brains19,35,36 and disruptions to regional blood flow-glucose
metabolism coupling are potential markers of brain dysfunction37. In general, a good
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correlation between perfusion and glucose uptake was observed in this study over the
entire brain. Regional variability in relative correlations was found, with the highest
correlations in the occipital and caudate, and the lowest in the limbic structures regardless
of the MRAC method used (Table 4.3). However, associations between perfusion and
PET signals reconstructed with Dixon+bone closely resemble patterns of regional relative
perfusion to glucose metabolism reported elsewhere, with FDG-PET and PET perfusion
tracers18,20,38, and with FDG-PET and ASL using standalone PET and MRI
scanners19,39,35.
When compared to Cha et al19, where similar regions were explored with a similar
pCASL labeling scheme, higher regional correlations of rCBF to rPETdxbone were
observed in the current study, except in the insula and putamen (Table 4.3). This apparent
increase (~30%) in regional coupling of perfusion to glucose metabolism is likely a result
of the improved registration accuracy provided by simultaneous imaging and the
improved tSNR provided by using a 3D pCASL method23,40. The temporal SNR of 3DGRASE pCASL was not compromised by the use of a PET-compatible head coil, and the
mean tSNR reported here was in line with values reported elsewhere23,40.
Results from voxel-by-voxel t-tests between rCBF and rPET demonstrated
regions of hyper- or hypo-perfusion not matched to glucose metabolism (Figure 4.5 and
Table 4.4). These findings, specifically from PET data corrected with Dixon+bone
MRAC, are in line with previous findings of increased resting perfusion to resting
metabolism in areas of the brain associated with the default mode network18,19,
suggesting that these brain regions require increased blood flow due to the sustained state
of arousal36. Apparent bias in bone attenuation from standard Dixon MRAC was evident
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in the comparison between relative perfusion and glucose uptake as demonstrated in
Figure 4.5 and in comparison to previous studies19,35,39. In particular, unexpected
increases in rCBF were observed in the left paracentral, left inferior parietal and right
superior temporal gyrus when compared to PETdx. The spatial pattern of these
differences, notably their occurrence closer to the edge of brain, is suggestive of
attenuation errors. Indeed, these regions of elevated rCBF were either removed or
significantly reduced when compared to PETdxbone.
It is possible that segmentation errors such as voxel misclassifications in
Dixon+bone µ-maps could account for some differences in correlations between the
current study and observations reported elsewhere. Differences in µa for bone assigned to
MR or CT derived µ-maps, and differences in PET scanner geometry and reconstruction
parameters including number of iterations, subsets and smoothing kernels could also
influence final observations. In addition, limitations inherent to pCASL and to PET-FDG
imaging such as partial voluming, differences in cellular localization of blood water and
FDG tracers, and optimal selection of post-labelling delay in ASL with minimal
compromise to SNR could affect accuracy of regional comparisons (cf. Cha et al19). The
evaluation of Dixon+bone µ-maps would have benefited from comparison to ground truth
using CT data, which was not feasible in this study. The PET-CT whole body survey
acquired on all subjects prior to PET-MRI imaging, permitted coverage solely from the
level of the eyes to the thighs as per clinical protocol, limiting whole brain comparisons.
As such, absolute and regional performance of the enhanced Dixon µ-maps was not
evaluated. Over estimation of bone information was observed in the inferior regions of
the brain and can be seen in the Dixon+bone µ-maps (Figure 4.1) and in the comparisons
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of PETdxbone to pCASL CBF (Figure 4.5). Regions close to the base of the skull where
bone anatomy is thin can yield low MR bone signals with MPRAGE25 or UTE4
sequences, and these regions are prone to signal misclassification errors in soft
tissue/bone/air interfaces in areas around the sinuses- an issue that affects most atlasbased MR-derived attenuation correction methods. Efforts were made to minimize bone
misclassification by morphological filtering of non-bone voxels. A recent study
demonstrated that SPM8-based method for generating MRAC is robust with a reported
accuracy of under 4% when compared to CTAC29. The results presented here were in
good agreement with previous studies, suggesting that these issues had little or no effect
on the study outcome. This suggests that ASL-CBF imaging could be used to in future
studies to investigate the relationships between altered brain function and disease-specific
PET tracers. The regional correlation of pCASL CBF to FDG-PET demonstrated here for
the first time with simultaneous imaging can be further improved with imaging of
concurrent uptake of the pCASL and FDG tracer.
In general, the agreement between this study and previous studies using CT
attenuation maps indicate that Dixon attenuation maps enhanced with bone information
from high resolution T1-weighted images can provide a feasible method for correction of
PET signal attenuation in PET-MRI neuroimaging. Errors in MRI-derived attenuation
correction maps including tissue misclassification can be further minimized by methods
that employ tissue classifiers from CT atlas to better guide segmentation of UTE or
MPRAGE data13.
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Chapter 5
Conclusions and Future Work

5.1

Summary of Findings

This thesis explored the role of cardiovascular disease in advancing pathological
brain aging using novel neuroimaging techniques. As well as investigated the
potential neuroprotective benefit of aerobic exercise training performed as part of a
cardiovascular rehabilitation (CR) program. Magnetic resonance imaging (MRI)
methods were used to measure gray matter volume (GMV) changes and changes in
cerebrovascular hemodynamics, specifically CBF and CVR, in a group of coronary
artery disease patients (CAD). In this final chapter, major findings of the studies
performed in this thesis are summarized. The clinical relevance of the findings is
discussed and areas of possible future directions are outlined.

5.1.1

Changes in Brain Structure Associated with Cardiovascular
Disease
Although prior evidence demonstrated decreased brain volume in older adults

with increased risks for cardiovascular disease1, changes in regional brain volume have
not been previously investigated in individuals diagnosed with cardiovascular disease.
Chapter 2 describes an exploratory study where regional GMV was compared between
CAD patients and age-matched controls using voxel-based morphometry, to examine the
impact of cardiovascular disease on brain structure. CAD patients exhibited decreased
GMV in the frontal, temporal and parietal lobes, and in the posterior cerebellum. These
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findings are in line with patterns of brain atrophy previously reported in hypertensive and
diabetic patients1, and support evidence of accelerated cognitive decline in cardiovascular
disease patients2. In general, the results suggest that cardiovascular disease accelerates
brain aging, affecting regions that are typically stable during normal aging.

5.1.2

Impact of Cardiovascular Disease on Brain Hemodynamics
Since CAD is a by-product of atherosclerosis and impaired cerebrovascular

hemodynamics are associated with markers of atherosclerosis, such as arterial stiffness3,
it follows that brains of CAD patients showing signs of structural decline (chapter 2)
would also have disruptions in hemodynamics. In chapter 3, cerebrovascular
hemodynamics (i.e., CBF and CVR) and relationships between hemodynamic changes
and brain atrophy was studied in the same cohort of CAD patients and controls.
Continuous measurements of cerebrovascular hemodynamics were performed during
acquisition of ASL images while subjects breathed room air (baseline) or hypercapnic air
(6% CO2, 21% O2 and balanced air) for 5 min each. Reduced resting CBF was observed
in CAD patients in the superior frontal, anterior cingulate, pre-and post-central gyri, and
superior temporal regions, along with decreased CVR in the anterior cingulate, post
central and superior temporal regions. These changes were independent of changes in
brain volume, suggesting that cerebrovascular dysfunction precedes brain atrophy.

5.1.3

Potential Neuroprotective Benefits of Cardiac Rehabilitation
Since established exercise-based preventative programs are readily available to

cardiac patients and a myriad of evidence demonstrates positive effects of exercise4, the
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potential neuroprotective benefits of physical activity on the brains of CAD patients were
explored. Chapters 2 and 3 describe pre- and post-intervention results from CAD patients
for whom declines in regional brain volume, CBF and CVR were observed preintervention. The exercise intervention consisted of a moderate intensity aerobic fitness
training lasting 6 months. Findings of increased brain volume in several regions of the
brain associated with cognitive control, as well as regions linked to motor coordination,
showed for the first time, the significance of exercise-based CR programs on brains of
CAD patients. Equally notable was the discovery of recovery in CBF in the anterior
cingulate and brain volumes in the superior frontal, superior temporal and posterior
cerebellum. These findings were in brain regions where a measurable decrease was
observed before rehabilitation. For instance, a ~33% decrease in CBF was observed at
baseline in the right anterior cingulate in CAD patients compared to control, while a
~30% increase in CBF was seen post exercise.

5.1.4

Can CBF Measured with ASL Serve as a Suitable Marker of
Brain Function
Current studies suggest that CBF measured with ASL correlates with cerebral

glucose consumption (CMRglc) measured with PET-FDG5–7, a well established measure
of brain function, and could serve as suitable alternative to PET-FDG8. However these
studies were performed using separate MRI and PET scanners and, therefore, voxel-wise
comparison of CBF and CMRglc could be confounded by image registration errors and
differences in brain physiological state between imaging sessions. Chapter 4 describes
efforts to correlate ASL-CBF to PET-CMRglc acquired simultaneously on an integrated
PET and MRI system. Marked regional variations in CBF to CMRglc were observed with
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the highest associations in the caudate and cingulate and the lowest in the limbic
structures. All findings were well matched to observations from previous studies,
suggesting that perfusion and glucose metabolism are well matched, but variable
distribution of perfusion to glucose metabolism coupling exist in healthy brains.

5.2

Relevance of Findings

In this thesis, neuroimaging in cardiovascular disease showed a pattern of brain
decline that is more severe than changes observed in normal brain aging, but reversible
with moderate aerobic exercise training. The findings from studies described in this thesis
bear some clinical relevance. First, the findings challenge the monodisciplinary approach
currently applied to management of cardiovascular disease in older adults. It is clear that
the brain is affected from cardiovascular disease, specifically diseases of atherosclerotic
origin. Individuals with a history of cardiovascular disease or at an increased risk for
vascular disease are more likely to have stroke and related cerebrovascular disease9. If the
expected increase in population of older adults includes an equal increase in
cardiovascular disease survivors, a better understanding of the complex interaction
between cardiovascular dysfunction and brain health is imperative, and will require a
multidisciplinary approach. The studies in this thesis provide a framework for further
multidisciplinary investigations, as will be discussed below. Second and more
importantly, the work presented here emphasizes the clinical significance of exercisebased CR programs in terms of benefit to both cardio- and cerebrovascular health. In
Canada, although exercise-based CR programs have been established for over 40 years,
only 1 in 3 eligible patients participate in CR10. A major source for underutilization is the
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lack of physician referral to CR11. The work laid out in thesis demonstrates the need for
further research in current CR delivery models to see if inclusion of cerebrovascular
health assessment and monitoring can improve overall efficacy of rehabilitation
programs.

5.3
5.3.1

Future work
Longitudinal and Epidemiology studies

Although the results presented in chapters 2 and 3 provide strong evidence of
cardiovascular disease effects on cerebrovascular structure and function, the crosssectional nature of study design, provides a snapshot at best of cardiac disease effects.
Longitudinal studies of disease progression may reveal further information of cardiac
disease contributions to brain dysfunction. For instance, in the Baltimore Longitudinal
Study of Aging, regional CBF was measured in healthy older adults and treated
hypertensive patients over a period of 6 years12. The study found an accelerated decrease
in regional CBF in the frontal, anterior cingulate and occipital regions over time, but the
duration of hypertension only contributed to decreased CBF in the frontal and anterior
cingulate regions12. Another longitudinal study of older adults with cardiovascular
disease measured diverse domains of cognitive performance using a battery of
neuropsychological tests, at study entry, 1 year and 3 years later2. The study reported
worsening of cognitive performance across all measured domain, but varied trajectory of
decline with faster decay for visuospatial skills and smaller relative rate of decline for
executive function and psychomotor speed2. Both studies demonstrate that certain brain
regions have a greater vulnerability to vascular disease over time. It would be interesting
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to observe changes in brains of CAD patients over time and examine the disease effects
as the brain ages.

5.3.2

Exercise
The neurovascular benefits of low-moderate intensity exercise programs

performed over a short period time (few weeks to 6 months) in healthy older adults are
still being explored. Current knowledge of long-term effects is limited and has only been
explored in one study, which found that walking at least 72 city blocks a week was
associated with preserved GM volume 9 years later, but walking more than 72 blocks did
not incur any added benefit13. Lingering questions on exercise threshold effects, that is
the minimum exercise duration and intensity required to detect structural and functional
brain changes, are yet to be clearly addressed. For individuals with cardiovascular
disease, exercise can be both beneficial or detrimental to cardiovascular health and
overall well being14, particularly when performed in unsupervised environments. In
addition, standard pharmacological therapies for management of cardiovascular disease
such as statins, beta-blockers and aspirin, are known to attenuate exercise effects15 and
modulate CBF16. An immediate question to address would be: does a single duration of
exercise training, for instance a 6-month aerobic exercise regimen such as in CR, confer
long-term neuronal protection for cardiovascular disease patients?
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5.3.3

Characterizing white matter structure in coronary artery
disease patients.
White matter (WM) lesions are prevalent in individuals with increased risk for

vascular disease17. Cerebral hypoperfusion is thought to significantly impair WM
connectivity affecting the speed of cognitive processing18. In healthy older adults, higher
cardiorespiratory fitness is associated with preservation of age-related declined in WM
microstructure19. Associations of vascular disease to disruptions in WM structural
integrity and subsequent effects on cognitive function are unclear. It is quite possible that
reports of accelerated cognitive decline in cardiovascular disease patients2 could be
linked to disruptions in WM integrity that are related to vascular disease 20. In the same
token, improvements in cognitive performance ascribed to exercise training21 could be
mediated by exercise-induced plasticity of WM structure22. Therefore, it would be
interesting to elucidate WM regions vulnerable to cardiovascular disease, investigate
relationships of WM abnormalities to cognitive impairments, and explore the role of CR
in mediating disease effects on WM microstructure.
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Appendices

Appendix A: An Overview of the Optimized VBM approach as implemented in
SPM8

Figure A1 : Flow chart of optimized VBM as implemented in SPM8.

In optimized VBM1 [1], the original T1 image volume in native space is
segmented into GM and WM images, followed by the removal of unconnected non-brain
voxels in skin, skull and dura from the segmented images using fully automated
morphological operations (erosion and conditional dilation). [2] The resulting GM and
WM images are spatially normalized to GM/WM templates further eliminating
contributions of non-brain voxels and improving spatial normalization of GM/WM
images. [3] The normalization parameters are then applied to the original T1 image
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volume placing the images in stereotactic standard space. [4] Subsequent segmentation of
the normalized T1 images into GM, WM and CSF partitions is performed to generate a
GM concentration map. [5] Spatial smoothing is applied to the GM map by convolving
the images with an isotropic Gaussian kernel. This renders the data more normally
distributed and compensates for the inexact nature of the spatial normalization. [6]
Finally, a generalized linear model fit is applied to the smoothed GM images for group
comparisons or correlations with covariates of interest.
Alternatively, segmented GM images in spatial correspondence to the template
can be [4a] multiplied ("modulated") by the Jacobian determinant derived from the
spatial normalization step [2]. This compensates for the non-linear effect of spatial
normalization and preserves the total amount of GM in the normalized data1. Individual
variations in brain sizes can be accounted for by either including the total intracranial
volume, which is the sum of GM, WM, and CSF, as covariates of no interest during the
statistical model fit (i.e. global normalization), or by modulating only the non-linear
components of the Jacobian determinant, which is recommended (dbm.neuro.unijena.de/vbm/). Hence, unmodulated smoothed normalized GM images represent relative
concentration of GM while modulated smoothed normalized GM images can represent
absolute volume of GM or relative volume corrected for differences in brain sizes. In
chapter 2 and 3, absolute GM volumes corrected for differences in brain sizes were used
to investigate regional differences in brain structure.
To improve signal-to-noise ratio and the sensitivity of detecting local changes in
gray matter, the T1 images are bias corrected for image intensity non-uniformity prior to
segmentation and the resultant GM volume or concentration maps are smoothed by

178

convolving the images with an isotropic Gaussian kernel. Bias correction accounts for the
smooth intensity variations due to spatially-dependent response of the head receiver coils.
While spatial smoothing renders the data more normally distributed and compensates for
the inexact nature of the spatial normalization. However, since spatial smoothing can blur
an image minimizing the ability to detect local changes, the size of the Gaussian kernel
should match the size of the expected effect.
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